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Summary 
Humans are daily exposed to a wide variety of man-made chemicals through food, consumer 
products, water, air inhalation etc. For the main part of these chemicals no or only very limited 
information is available on their potential to cause endocrine disruption.  Traditionally such 
information has been derived from animal studies, which are time-consuming, expensive and subject 
to ethical issues. For these reasons alternative methods such as cell culture studies and non-testing 
approaches such as quantitative structure-activity relationships (QSARs) are of high value as they can 
provide information on the mode of action of chemicals in a faster and cheaper way. The main 
purpose in this PhD project was to develop QSAR models for mechanisms related to endocrine 
disruption and apply the models to predict 10,000s of chemicals to which humans are potentially 
exposed. 
The first part of the thesis is a background section, comprising 1) an introduction to the endocrine 
system with a focus on thyroid hormones (THs) and their essential function in neurodevelopment as 
well as a description of how chemicals may interference with endocrine mechanisms and cause 
adverse effects, 2) an introduction to the applied methods to develop QSARs, and 3) an introduction 
to regulatory toxicology including the acceptance of predictions from QSARs under the European 
chemicals regulation, REACH. Following the background section, the four projects of the thesis are 
described. The first three projects focus on the development of QSARs for mechanisms that can 
affect TH levels: Thyroperoxidase (TPO) inhibition, Pregnane X receptor (PXR) activation, and Aryl 
hydrocarbon receptor (AhR) activation. TPO is an enzyme essential in the synthesis of THs, and both 
PXR and AhR are important regulators of enzymes involved in the turnover of THs and other 
hormones. The fourth project was part of a large international QSAR collaboration, CERAPP, in which 
a QSAR model for estrogen receptor (ER) agonism was developed, and used to predict 32,197 
CERAPP chemicals. All models in the four projects were validated to assess how good they are at 
making correct predictions, and they all showed good predictive performance. The QSAR models 
were used to predict 72,524 REACH substances, and they were able to predict between 38,114 to 
53,433 of these substances. 
To conclude, the QSAR models developed in this PhD project can provide important information on 
the 10,000s of chemicals in our surroundings. The predictions can for example be used for 
prioritizing chemicals for further evaluation, aid in chemical assessments, grouping approaches, and 
drug development as well as in the generation of new hypotheses on mode of actions in adverse 
health outcomes. 
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Dansk Resumé 
Mennesker udsættes dagligt for mange forskellige kemikalier fra fx madvarer, personlig pleje 
produkter, vand og luften. For størstedelen af disse kemikalier er der ingen eller kun meget 
begrænset viden om deres potentielle hormonforstyrrende effekter. Traditionelt har man indsamlet 
denne information fra dyreforsøg, men de er tidskrævende, dyre og etisk problematiske. Alternative 
metoder såsom celleforsøg og computermodeller som f.eks. quantitative structure-activity 
relationships (QSARs) kan bruges til på en hurtigere og billigere måde at forstå kemikaliernes 
virkningsmekanismer. Hovedformålet med dette PhD projekt var at udvikle QSAR modeller for 
mekanismer i hormonsystemet, og benytte disse modeller til at screene 10.000’er af kemikalier, som 
mennesker potentielt udsættes for. 
Første del af afhandlingen består af et baggrundsafsnit, der 1) introducerer hormonsystemet med 
fokus på thyreoideahormoner (TH’er), som bl.a. er essentielle i udviklingen af hjernen, samt 
beskriver, hvordan kemikalier kan påvirke mekanismer hormonsystemet og derigennem forårsage 
sundhedsskadelige effekter, 2) introducerer de metoder der anvendes i udviklingen af QSAR 
modeller, og 3) introducerer den regulatoriske toksikologi, og hvordan QSAR forudsigelser bl.a. kan 
benyttes i den Europæiske kemikalielovgivning, REACH.  
I næste del beskrives afhandlingens fire projekter. I de første tre projekter blev der udviklet QSAR 
modeller for mekanismer, som påvirker TH niveauet: Thyroperoxidase (TPO) hæmning, Pregnane X 
receptor (PXR) aktivering, og Aryl hydrocarbon receptor (AhR) aktivering. TPO er et vigtigt enzym i 
syntesen af TH’er, og både PXR og AhR er vigtige i reguleringen af enzymer involveret i omsætningen 
af TH’er og andre hormoner. Det fjerde projekt var en del af et stort internationalt QSAR 
samarbejde, CERAPP. Hertil blev der udviklet en QSAR model for østrogen receptor aktivering, en 
vigtig mekanisme for hormonforstyrrende kemikalier, og modellen blev brugt til at forudsige 32.197 
CERAPP kemikalier. Alle modellerne blev valideret for at vurdere deres evne til at lave korrekte 
forudsigelser, og de viste alle høje nøjagtigheder. Modellerne blev efterfølgende bl.a. brugt til at 
forudsige 72.524 REACH stoffer, og de kunne forudsige mellem 38.114 og 53.433 af stofferne. 
De udviklede QSAR modeller kan bidrage med værdifuld information om de 10.000-vis af kemikalier i 
vores omgivelser. Forudsigelserne kan bl.a. bruges til at prioritere kemikalier til yderligere 
toksikologisk vurdering, samt blive brugt i evalueringen og grupperingen af kemikalier, i udviklingen 
af lægemidler og i opstillingen af nye hypoteser om underliggende virkningsmekanismer i 
sundhedsskadelige effekter. 
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1.1 Motivation and Scope of the Project 
Humans are continuously exposed to a wide variety of man-made chemicals through for example 
food, water, consumer products such as cosmetics and house-cleaning products, pharmaceuticals, 
and air inhalation [1–4]. These chemicals have the potential to interfere with normal physiological 
systems of living organisms and, if the interferences are left uncompensated, adverse health effects 
may develop. Evidence from epidemiological studies indicates that chemical exposure is involved in 
a number of adverse human health effects such as cancer, reduced reproductive health and learning 
disabilities [5–11]. Some of these adverse outcomes are likely the result of chemical interference 
with molecular mechanisms of the endocrine system such as interaction with hormone receptors 
and/or altered synthesis, degradation or transport of natural hormones [8,12]. This has led to an 
increased focus on identifying chemicals with endocrine modulating properties, i.e. so-called 
endocrine disrupting chemicals, and screening for a battery of such properties has been included in 
programs and legislations within both EU and US [4,13,14].  
Traditional toxicology testing consists of exposing laboratory animals, typically rats or mice, to a 
chemical and looking for adverse effects at whole animal, tissue and/or cellular level. Animal tests 
are time-consuming, expensive, subject to ethical issues, and their results can be difficult to 
extrapolate to humans [15–18]. Due to these challenges/limitations with animal toxicity tests and 
the ongoing need to gather toxicity information on the many thousands of chemicals in commerce, a 
paradigm shift in toxicity testing have been proposed, often referred to as Toxicity Testing in the 21st 
Century [19,20]. Here the use of alternative methods such as in vitro and in silico to aid in chemical 
safety assessment is presented [19–22].  
In this PhD project, the in silico method Quantitative Structure-Activity Relationship (QSAR) 
modeling was applied on a number of molecular mechanisms within the endocrine system, most of 
which are molecular initiating events (MIEs) in established adverse outcome pathways (AOPs) of 
thyroid-related adverse outcomes [23–26]. The developed models underwent thorough validations 
according to regulatory recommendations [27] and were then used for screening of large chemical 
inventories containing man-made chemicals.  
The main hypothesis of this PhD project is: 
 
 
 
QSAR models for selected molecular mechanisms of thyroid-
related AOPs can expand the knowledge derived from 
experimental data and aid in human health safety evaluation of 
chemicals. 
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To investigate this hypothesis, the following questions have been sought answered:  
• Can highly predictive and robust global QSAR models for MIEs in relevant AOPs be 
developed? 
• If so, can such QSAR models trained on 1,000s of structurally diverse chemicals, provide 
reliable predictions and hereby extend the use of information from tested chemicals to 
10,000s of man-made untested chemicals? 
1.2 Organization of the Thesis 
The thesis is organized into four parts. Part I gives an introduction to the motivation for the PhD 
project, its scope, hypothesis and organization. In Part II a general background on the endocrine 
system and related toxicology with focus on the thyroid system is given followed by an outline on 
the concept of QSAR models and their applications, and finally an introduction to regulatory 
toxicology. The background sections in Part II are not exhaustive and more information on the 
different topics may be found in the published literature. Part III contains separate chapters 
describing each of the four projects of this thesis. Accepted papers, submitted manuscripts or study 
reports from each of the projects are included in the respective chapters. The final Part IV consists of 
a brief overview, a summarizing discussion and conclusion as well as further research perspectives.  
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2.1 The Endocrine System and Endocrine Disrupting Chemicals 
2.1.1 The Endocrine System 
The endocrine system is large and complex and serves multiple essential functions in the body such 
as regulation of body temperature, blood glucose levels, reproductive function and fetal 
development [1]. Briefly, the endocrine system ensures optimal communication between cells, 
tissues and organs of the body through hormone signaling to the responsive tissues. Hormones are 
synthesized in a number of tissues and organs, a few examples being the thyroid gland, ovaries, 
testes, hypothalamus, pituitary gland, adrenal glands, adipose tissue and pancreas (Figure 1) [1]. The 
hormones are released to the bloodstream and transported, often by plasma proteins, to their 
target tissue(s). Here a hormone can act directly on membrane receptors that transduce signals into 
the cell or it can enter the cell either by passive diffusion or active transport by membrane proteins 
[1]. In the cell, the hormone binds and activates its cognate hormone receptor, resulting in 
downstream effects such as production of proteins that facilitate biological responses [2]. The 
hormone-receptor interaction pathway is the best-characterized hormone signaling pathway but 
other modes of action of hormones also exist [3–6].  
Figure 1. A basic and non-comprehensive overview of the complex endocrine system with examples of 
hormones and their physiological functions. FSH, follicle stimulating hormone; LH, luteinizing hormone; T4, 
thyroxine; T3, triiodothyronine; TSH, thyroid stimulating hormone. 
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The plasma levels of hormones are generally kept within strict, but very individual, patterns by for 
example negative feedback loops [1,2,6]. With negative feedback loops the hypothalamus, pituitary 
and in some cases the hormone-producing tissues sense the plasma concentration of the hormone, 
and in case of a low hormone plasma level synthesis and secretion of the hormone is upregulated 
and vice versa with a high hormone plasma level. Hormones are metabolized and inactivated by 
enzymes in the target tissues and/or the liver, and are either reused or excreted via the bile or urine. 
The expression of the phase I and II liver metabolizing enzymes and the membrane transport 
proteins is regulated by nuclear receptors (NRs) such as the Pregnane X Receptor (PXR), the Aryl 
hydrocarbon Receptor (AhR) and Constitutive Androstane Receptor (CAR) [7,8]. 
2.1.1.1 Thyroid Hormones and Neurodevelopment 
Thyroid hormones (THs) are involved in multiple biological processes from early fetal development 
and throughout adulthood [6,9–11]. In early gestation, the fetus depends on maternally-derived THs. 
The fetal thyroid gland develops from the third week of gestation, and at approximately gestational 
week 12 in humans and gestation day 17.5-18 in rats, the fetal thyroid gland starts to synthesize THs 
from maternally-derived iodine [2,12]. However, maternal THs continue to contribute significantly to 
fetal TH levels throughout gestation in both humans and rats [10,13]. Consequently, the maternal 
thyroid gland has to increase its TH production during pregnancy to meet the needs of both fetus 
and mother [2].  
THs are synthesized in the follicles of the thyroid gland located on the anterior trachea (Figure 2a). 
Serum iodide (I-) is transported into the thyrocytes by the Na+/I- symporter (NIS) in the basal 
membrane and is further moved across the apical membrane by the anion transporter Pendrin to 
enter the colloid of the thyroid follicle [14,15]. Here I- is oxidized to hypoiodite (IO-) in the presence 
of dual-oxidase generated hydrogen peroxide (H2O2) by the multifunction, heme-containing enzyme 
thyroperoxidase (TPO) located in the apical thyrocyte membrane [14,16,17]. TPO further catalyzes 
the iodination of the tyrosyl residues on thyroglobulin (Tg), a glycoprotein secreted by the 
thyrocytes, to form monoiodotyrosine (MIT) and diiodotyrosine (DIT) [14,16,17]. The conjugation, 
again catalyzed by TPO, of DITs and MITs on Tg, leads to the formation of three THs: thyroxine (DIT + 
DIT, T4), triiodothyronine (MIT + DIT, T3) or reverse triiodothyronine (DIT + MIT, rT3), which is 
biologically inactive [18].  
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Figure 2. Overview of mechanisms in the thyroid system. See text for explanations and abbreviations. 
After being transported across the cell, the THs are released from Tg and secreted into the blood, 
where the hydrophobic THs are bound to three principal serum TH-binding proteins, thyroxine 
binding globulin (TBG), transthyretin (TTR) and albumin [19] (Figure 2b). TBG is the main TH plasma 
transport protein in humans, whereas in animals TTR is the most important transporter protein for 
THs [2]. TTR also plays a role in the transport of THs over the placenta and the blood-brain-barrier in 
humans [20,21]. When reaching the target tissue, free serum THs enter the cells by active 
transporters such as monocarboxylate transporter-8 (MCT-8) and organic anion transporter protein 
1c1 (OATP1c1) [10] (Figure 2c and 2e). T4 is the most abundant TH in the blood and is generally 
converted to the more potent T3 in the liver or locally in the target tissue by outer-ring deiodinase 
activity (ORD, deiodinase type 1 and 2) [2,10,22]. The effects of T3 is primarily exerted through the 
two cognate thyroid hormone receptors (TR), TRα and TRβ, which bind to thyroid hormone response 
elements (TREs) to modulate downstream gene transcription resulting in different outcomes 
depending on the target cell and tissue [10]. Besides regulating TR transcriptional activity, THs can 
also mediate non-genomic pathways, such as membrane signaling pathways, resulting in rapid 
(seconds to minutes) onset effects [6].  
The TH serum level is normally kept within a narrow range by the hypothalamus-pituitary-thyroid 
(HPT) axis, a multi-loop negative feedback system that ensures an appropriate balance between 
synthesis and degradation of THs [2,6] (Figure 2d). In response to low levels of THs in the blood, the 
pituitary upregulates the secretion of thyroid stimulating hormone (TSH), either as a direct response 
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or via thyroid releasing hormone (TRH) from the hypothalamus [6]. TSH binds to TSH receptors on 
the thyrocytes leading to a stimulation of TH synthesis and release [2]. On the other hand, when the 
TH blood level is high TSH secretion is downregulated resulting in decreased TH synthesis and 
release. Besides the control of TH levels by the HPT axis, TH levels can also be affected by TH 
catabolism. THs are primarily metabolized and inactivated in the liver by the phase II enzymes, 
sulfotransferases (SULTs) and UDP-glucuronosyltransferases (UGTs) [8,23–25], and by inner ring 
deiodinase activity (IRD, deiodinase type 1 and 3) in both the liver and other tissues [10] (Figure 2e). 
The expression of SULT and UGT isoenzymes is regulated by the xenobiotic NRs PXR, AhR, and CAR 
[7,23,26]. The modified and biologically inactive THs are eliminated via the bile or urine. 
In adulthood, THs are involved in blood glucose regulation, heart function and basal metabolic rate 
as well as many other biological processes [27,28]. Dysregulated TH levels can give reversible clinical 
symptoms of hypo- or hyperthyroidism [28] and are associated with pathological processes involved 
in adverse outcomes such as cancer, obesity and type II diabetes mellitus [29,30]. In the developing 
fetus and neonate, THs are involved in various developmental processes [28] and are essential in 
normal neurodevelopment [2,31]. Both in vitro and animal studies have shown the importance of 
THs in processes such as neuron differentiation, proliferation and migration, dendritic branching and 
synaptogenesis as well as myelination [10,32,33]. Studies have shown that even a moderate and 
transient decrease in maternal TH levels during pregnancy is associated with permanent adverse 
neurological changes in the offspring [2,28]. These changes include reduced IQ and altered 
cognition, socialization and motor function in children [34–39], and altered cognitive behavior and 
motor function as well as hearing loss in animals [13,40–42]. Alterations in maternal TH levels during 
pregnancy, for example due to iodine deficiency or untreated thyroid disorders, have also been 
associated with an increased risk of cretinism, autism spectrum disorders (ASD) and attention-
deficit/hyperactivity disorder (ADHD) in children [9,43–45].  
2.1.2 Endocrine Disrupting Chemicals 
An endocrine disrupting chemical (EDC) is, as defined by the World Health Organization (WHO) in 
the International Progamme on Chemical Safety (IPCS) report from 2002 [46]:  
‘an exogenous substance or mixture that alters function(s) of the endocrine system and consequently 
causes adverse health effects in an intact organism, or its progeny, or (sub)populations’.   
This definition is widely accepted as it is applicable to both human health and ecotoxicological 
hazard and risk assessment; however it is also relatively open for interpretation. Other definitions of 
EDCs with focus on the mode-of-actions of EDCs have been suggested [47], for example the EDC 
definition by Kavlock and others [48]: ‘an exogenous agent that interferes with the production, 
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release, transport, metabolism, binding, action or elimination of natural hormones in the body 
responsible for the maintenance of homeostasis and the regulation of developmental processes’. 
Depending on multiple factors such as the timing and length of exposure as well as dose and 
concurrent exposure to other EDCs, an EDC can modulate the endocrine system and potentially 
result in adverse effects [1,2,49]. In general, low and transient EDC exposure during adulthood can 
be compensated for and will often give undetectable or only temporary, reversible effects. Exposure 
to EDCs during fetal and neonatal development can result in serious and permanent later life effects 
such as learning disabilities and reduced fertility [1,50]. Because of the complexity of the endocrine 
system (Figure 1), the cross-talks between the different mechanisms [51,52] and the tempo-spatial 
aspects, it is difficult to predict if and how endocrine system modulations by EDCs will result in 
effects at the epi-molecular levels [1]. This is further complicated by interspecies differences in the 
endocrine effects, which is why extrapolation between results from in vitro, in vivo and clinical EDC 
studies should be made with precautions [1]. 
Multiple programs are screening chemicals for endocrine disrupting properties [32,53,54], and such 
programs have originally mainly focused on estrogen and androgen receptor interaction. The 
screening batteries have gradually been extended to cover other endocrine systems such as the 
thyroid system as well as other mechanisms within the endocrine systems for example the 
production and degradation of hormones [8,55–59]. The larger the EDC screening battery gets, the 
better the identification of potential EDCs becomes. Conceptually, one should keep in mind that a 
chemical can never be said to be without any endocrine modulating potential based on such 
screenings. Instead, the screenings can help identifying and prioritizing chemicals for further 
testing/evaluation and aid in the design of higher-tier toxicity testing protocols. They may also 
provide useful information in combination with AOP(s) to Integrated Approaches and Testing 
Assessments (IATA) in weight-of-evidence (WoE) assessments  as well as give useful information in 
the substitution to safer alternatives (see chapter 2.3).  
2.1.2.1 Thyroid Disrupting Chemicals and Developmental Neurotoxicity 
Neurodevelopmental disabilities including ADHD, ASD and IQ deficits are common and their 
prevalence’s seem to be increasing [60,61]. The causes of neurodevelopmental disabilities are not 
fully understood, but genetics and environmental factors such as exposure to man-made chemicals 
are involved [60,61]. Chemicals that interfere with one or more mechanisms in the thyroid system 
(Figure 2), i.e. thyroid disrupting chemicals (TDCs), can lead to altered TH levels [28]. Studies indicate 
that the majority of TDCs act by modulating the TH levels rather than direct interaction with the TRs 
in the target tissues [8]. Exposure to TDCs during pregnancy may lead to decreased maternal TH 
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levels potentially resulting in developmental neurotoxicity (DNT) and other adverse effects in the 
offspring [2,7,8,62–65]. Chemical interference with other endocrine and non-endocrine mechanisms 
may also result in DNT [66,67]. EDCs, and especially TDCs, with DNT potential have been 
demonstrated to contribute to neurodevelopmental disabilities [60,61,68]. The neurodevelopmental 
disabilities have multiple implications including reduced life quality and academic achievement, as 
well as disturbed behavior. These implications have profound economic consequences for societies 
[60,61], for example is EDC-related DNT estimated to cost Europe more than 150 billion euros per 
year [68].  
Because of the severity of the adverse effects and the economic consequences that can be expected 
from chemical disruption of thyroid homeostasis there is an urgent need to develop a strategy for 
the identification and testing of TDCs [8]. This has initiated a large international collaboration, which 
aims at developing and using new in vitro assays for DNT, including in vitro assays for thyroid-related 
mechanisms such as TPO, NIS and deiodinase interaction [66,69]. Such assays can be used for 
screening the many thousands of chemicals in commerce for which there is none or only limited 
data on their potential to be TDCs and/or cause DNT. These screening data can be used to either 
prioritize chemicals for further DNT testing or for inclusion in WoEs of IATAs, e.g. together with 
relevant AOP(s) and other data, in chemical-specific assessments (see section 2.3.4). 
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2.2 Quantitative Structure-Activity Relationship Models 
A QSAR model is a mathematical model that describes the quantitative relationship between 
chemical structures and their properties, e.g. a physico-chemical property or a biological activity. 
QSARs are trained on experimental data for chemicals with known structures using machine learning 
and statistical methods, and they can be used to predict the activity of chemicals based on their 
structures (see e.g. [1] and [2] for more in-depth reviews of QSARs). The quantitative in QSAR refers 
to the nature of the descriptors (i.e., independent variables) and the modeling method and not to 
the modeled endpoint (i.e., response variable), which can be either quantitative/continuous (e.g. 
IC50) or qualitative/categorical (e.g. active versus inactive) [1]. Closely related to QSAR is the simpler, 
structure-activity relationship (SAR) method that qualitatively relates a (sub)structure to an activity. 
In contrast with QSARs that result from statistical analyses of experimental data, SARs are usually 
based on expert knowledge and are encoded into expert systems [3]. Collectively, SARs and QSARs 
are referred to as (Q)SARs [1]. (Q)SARs are non-testing approaches and other related non-testing 
approaches include grouping approaches using e.g. read-across, and expert systems, which can be 
combinations of SARs, QSARs and databases [1]. Together these non-testing approaches are based 
on the structural similarity principle, i.e. the hypothesis that structurally similar chemicals exhibit 
similar behavior (in living organisms), and are used to facilitate the evaluation of properties of 
chemicals by extending existing information [1].  
QSARs date back to the late 1800s, when Hans Horst Meyer and Fritz Baum described the correlation 
between partition coefficients and tadpole alcohol narcosis [4–6]. The interest in QSARs has 
increased gradually [2,7] after the pioneering work in the 1960s by Corwin Hansch and colleagues, 
who made simple QSAR models for inhibition of photosynthesis and activity of auxin, a plant growth 
substance [8–11]. Since then advances in technology, mathematical methods, and computer power 
have allowed for efficient development of much more complex and predictive QSAR models. Today 
QSAR models are widely used in academia, industry and agencies [2].  
2.2.1 QSAR Development  
The development of QSAR models follows a general workflow starting with 1) dataset collection, 
curation and preparation, 2) generation and selection of chemical descriptors to be used as 
independent variables in 3) the model building step, and finally 4) a statistical validation of the 
model(s) within the defined applicability domain (AD) (Figure 3) [12]. A QSAR model is built using a 
so-called training set, which consists of chemical structures and related experimental data. The 
chemical structures are represented by chemical descriptors (see more in 2.3.1.2), which are used as 
independent variables in the model. The experimental endpoint, which can be either continuous or 
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categorical, is used as the response variable in the model. QSARs are normally classified as global or 
local. A local QSAR is trained on a small and congeneric series of chemical structures, whereas a 
global QSAR is trained on a large and structurally diverse set of chemicals. The term validation is 
broadly defined as “the process by which the reliability and relevance of a particular approach, 
method, process or assessment is established for a defined purpose” [13]. However, this definition is 
rather abstract in a QSAR context and therefore a more operational definition of validation has been 
proposed [14]:  “The validation of a (Q)SAR is the process by which the performance and mechanistic 
interpretation of the model are assessed for a particular purpose”. The performance assessment 
here refers to the statistical validation of the model [1]. The AD as a general term is defined as “the 
response and chemical structure space in which the model makes predictions with a given reliability” 
[15] (see more in section 2.2.2).  
Figure 3: Overview of the basic QSAR development steps. See text for an explanation of the figure. 
Many different methods for each of the steps in 1) to 4) have been proposed and used (see e.g. 
[7,12,16,17]). Here a basic and non-comprehensive workflow is introduced and some of the methods 
and caveats are briefly discussed (Figure 3).  
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2.2.1.1 Data Collection, Curation and Preparation 
As the quality of the data strongly influences the quality and performance of the built QSAR model 
[16,18–20], the steps of data collection, curation and preparation are of high importance in QSAR 
development and should follow some basic principles [2] (Figure 3, 1). 
2.2.1.1.1 Data Collection 
The first step when developing a QSAR model is to collect a dataset containing structure and 
experimental endpoint information for a set of chemicals [12,16,21–23]. The chemical structures in 
the dataset should be represented in a computer-readable 2D or 3D format, three of the most 
widely used ones being SMILES (simplified molecular input line entry system) [24–26], the 
connection table format (used in MOL or SDF files) [27] and InCHI (IUPAC International Chemical 
Identifier)1. Most QSAR models use 2D structure information but 3D-QSAR models also exists [28–
31] and 4- and higher-dimensional approaches have been reported [32]. Preferably the dataset 
should be collected from a single reliable source and have experimental data for a well-defined 
endpoint that have been produced in the same laboratory by the same personnel and have followed 
the same experimental protocol(s) and subsequent data analyses [1] (Figure 3, 1a).  
2.2.1.1.2 Data Curation 
At this step, the quality of both structure and experimental information in the collected dataset 
should be thoroughly evaluated as errors in the data can strongly influence the performance of the 
developed model [2,12,16,21–23,33]. Several studies have shown that structural errors are not 
uncommon, and therefore identification and correction of such structural errors should be part of a 
standardized data curation strategy [12,23,33,34]. Often the software systems used for interpreting 
the structures and/or building the models are limited in the chemical universe they can handle, and 
most QSAR models are based on organic discrete 2D chemical structures. Inorganic or 
organometallic compounds and mixtures can generally not be handled by conventional 
cheminformatics tools and need removal [2]. The remaining structures need to undergo a 
standardization and normalization procedures to ensure that all structures are described following 
the same algorithm, i.e. are canonized, in terms of e.g. ring aromatization and neutralization [2,26]. 
When these steps have been applied the chemical structures are made ‘QSAR-ready’ (Figure 3, 1b). 
The quality and reproducibility of the experimental data should be assessed. In general, with regards 
to the quality and reproducibility of the experimental data the model developer has to rely on the 
information from the data provider(s). Often a description of the experimental protocol(s) and 
performance as well as the applied data analyses is available to the model developer. The model 
                                                     
1 https://iupac.org/who-we-are/divisions/division-details/inchi/ 
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developer should become familiar with the nature of the experimental data and its underlying 
biology and assay technology to assess the degree of uncertainty/artefacts and potential false 
results. Based on this, measures should be taken to identify unreliable experimental results. For 
example corresponding experimental data from counterscreen assays, e.g. for luciferase interaction, 
can be applied to identify non-specific and potential false experimental results. If the data have been 
collected from multiple sources it can contain additional uncertainties from e.g. interlaboratory 
variability and/or differences in the test protocols and data analyses. Such uncertainties are likely to 
introduce extra noise and reduce the performance of the model compared to models built from data 
from a single source undergoing the same test protocol(s) and data analysis [1,7,35] (Figure 3, 1b).  
Next, any replicated ‘QSAR-ready’ structures in the dataset should be identified and the 
experimental values of the identified structural replicates should be compared [2]. If the replicates 
have the same experimental results then only one of the structures should be kept as they will 
otherwise be given too large influence in the model. For a set of replicates with discrepant 
experimental results different removal approaches can be used, e.g. removing all replicates or, for a 
continuous response variable, an average value can be calculated and kept together with one of the 
structures [2,36] (Figure 3, 1b).  
When the replicates have been handled, a final general manual inspection of the dataset should be 
made as the last step of the data curation and can include checking that previous curation steps 
have been successful and identification of outliers [2,16] (Figure 3, 1b). Manual inspection is 
however not practical in case of very large datasets and may be skipped in such cases. Briefly, 
outliers can be of the ‘activity cliff’ type or due to errors in structure information or experimental 
data not taking into consideration in the previous steps [21,37]. There are different approaches 
about outliers. In principle, all available experimental data are valuable and should be used in the 
construction of a QSAR model. However, outlier removal if done independent of the model results 
can be justified in some situations. For example in the development of smaller, local QSAR models 
based on a dataset of congeneric chemical structures that act by a common mechanism, a correct 
experimental result may be treated as an outlier if it is known that the chemical acts by a different 
mechanism than the one for the majority of the training set. Overall, if measures are taken to 
remove outliers, a good explanation should be provided along with a detailed documentation of the 
removal procedure, otherwise the outlier removal step can be interpreted as a manipulation of data 
with the purpose of artificially improving model performance [2,38].   
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For preparing a prediction set, i.e. a dataset containing only chemical structures that are planned for 
screening through the QSAR model to generate predictions for their activity, the data collection and 
curation steps regarding structures also apply.  
2.2.1.1.3 Data Preparation 
When the data have been properly curated, the next step is to decide whether the curated dataset 
should be used as a training set or if it should be split into training and test sets [12,39] (Figure 3, 1c). 
In the last case, different splitting methods can be used such as random splitting or a rational 
stratified splitting on endpoint activity or descriptor space [17,39–41]. Each splitting method will 
have its pros and cons with regard to model coverage and performance as well as the interpretation 
of the external validation estimations [40,42]. In general, rational splitting will result in a test set 
more similar to the training set and may, if the test set is too similar, give overoptimistic future 
predictive performance and coverage measures compared to a test set made from random splitting, 
which better represents the future non-selected prediction sets [2,36,40]. Some things to consider if 
the dataset is split, besides the splitting method, are the absolute and relative sizes of the training 
and test sets. Often the size of the test set(s) is between 10% and 30% of the dataset [39], and the 
remainder of 70% to 90% is used for model training. The absolute size of the test set should be large 
enough to be used for robust external validation [12,17,43], and similarly the training set should, at 
least for global QSAR development, have a certain size and diversity to avoid chance correlations and 
overfitting. Fixed cut-offs for the lower limits of the size of the training and test sets cannot be set 
[12] as this depends on the nature of the full dataset, the types of chemical descriptors and 
statistical methods being used, the purpose of the model etc. [39].  
Due to the increasing implementation use of high-throughput screening (HTS) assays such as those 
applied in e.g. the ToxCast and Tox21 programs (see section 2.3.2), it is more and more common to 
find datasets with a binary response variable that are very imbalanced towards a larger class of 
inactives [12,44]. Generally, a QSAR model trained on such imbalanced dataset has a tendency to be 
biased towards making predictions for the majority class (Figure 3, 1c). For the typical imbalanced 
training set with a bigger inactivity class this will likely result in a model with a high specificity and a 
low sensitivity (see definitions in Figure 4) upon predictive performance evaluation [45]. To 
overcome this problem different approaches to balance the training set have been suggested 
[12,44,46,47] such as undersampling of the bigger class or oversampling of the smaller class [48,49].  
2.2.1.2 Descriptor Generation and Selection 
To build a QSAR model a set of descriptors encoded within chemical structures of the curated 
training set first needs to be generated (Figure 3, 2). Chemical descriptors are values that describe 
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different properties of a molecule. They can be physico-chemical characteristics (e.g. molecular 
weight and logP), topological (e.g. atom, bond and ring counts), steric (e.g. volume and surface) or 
electronic (e.g. HOMO and LUMO). A special class of descriptors is structural descriptors or features. 
Pre-defined sets of structural features, also called structural keys (e.g. MACCS keys [50]) and the 
Leadscope Structural Feature Hierarchy [51]), can be used by searching for the pre-defined structural 
keys in the chemical structures of the training set. The presence or absence of each key in a 
structure is encoded in a bitmap, where each bit represents a 1 if the key is present and a 0 if it is 
absent. The structural keys can also be used for constructing new, larger structural features [52]. 
Furthermore, structural features can be molecule-dependent, i.e. so-called fingerprints, rather than 
pre-defined. Structural descriptors in fingerprints are created using a fingerprinting algorithm (e.g. 
the Daylight fingerprints [53]) that examines the molecule and generates a set of patterns [54]. 
Besides being applicable in QSAR modeling, structural features from both structural keys and 
fingerprints are also used to calculate structural similarity measures such as the Euclidean distance 
or the Tanimoto/Jaccard coefficient [53,55]. Transformation, i.e. normalization and/or autoscaling, 
of continuous chemical descriptors and/or the response variable might be necessary at this step as 
large variabilities in the range and distribution of these can pose a problem for some 
statistical/machine learning methods [2,7].  Examples of commercial and free software tools for 
generating chemical descriptors include MOE2, DRAGON3, RDKit4, PaDEL5 and CDK [7,56–59].  
The number of generated chemical descriptors for a training set is often huge and many of the 
descriptors may be correlated or redundant (Figure 3, 2). Examples of redundant descriptors include 
those only present in a single structure or descriptors with the same or almost same value over all 
samples in the dataset. Different unsupervised data reduction techniques for removing or 
minimizing redundant information are available, an example being the principal component analysis 
(PCA) that creates uncorrelated latent (i.e., hidden/non-observable) variables from the descriptors 
[54,60,61]. After removing redundant and correlated descriptors, the next step is to select the 
descriptors that should be included in the model algorithm. Multiple descriptor selection techniques 
are applied in QSAR development, all with the purpose of finding a combination of descriptors for 
QSAR modeling of the response variable [62–64]. The selection techniques include supervised 
methods such as wrapper methods (e.g. genetic algorithms (GAs)), and filter methods (e.g. 
univariate data analysis) [65]. Each method has its advantages and limitations in terms of e.g. 
computation time and ease of implementation [62–64,66]. The descriptor reduction and selection 
                                                     
2 https://www.chemcomp.com/MOE-Cheminformatics_and_QSAR.htm 
3 http://www.talete.mi.it/products/dragon_description.htm 
4 http://www.rdkit.org/ 
5 http://www.yapcwsoft.com/dd/padeldescriptor/ 
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procedures have been used to reduce computation time, improve model predictive performance, 
and ease interpretability as well as avoid overfitting and reduce chance correlations [62,63,67]. A 
general recommendation is that the training set chemicals to chemical descriptors ratio of a model 
should be at least 5:1 in order to minimize the risk of chance correlations and overfitting [2,35,68].  
2.2.1.3 Machine Learning and Statistical Methods in QSAR building 
Various QSAR modeling methods exist, and new methods are continuously being developed [69] 
(Figure 3, 3). Depending on whether the response variable is continuous or categorical either 
regression or classification methods, respectively, should be applied in the QSAR building. In general, 
classification models tend to be more flexible and successful in prediction [70]. A continuous 
response variable can be made categorical by using one (i.e. binary) or more cut-offs, which can be 
set based on different criteria such as model performance or a biological rationale [12,41,71].  
The list of classification and regression methods applied in QSAR building is long [69,72]. A few non-
exhaustive examples of linear and non-linear classification and regression methods used to build 
QSAR models are listed in Table 1.  
Table 1. Examples on the use of classification and regression methods in QSAR building 
Examples Use cases References 
Classification 
Linear discriminant analysis (LDA) 
k-nearest neighbors (kNN) 
Naïve bayes (NB) classification  
Support vector machines (SVM) 
Random forest (RF)  
Partial logistic regression (PLR) 
Classification and regression trees (CART)  
[39] 
[71] 
[73] 
[73,74] 
[73,74] 
[36] 
[75] 
Regression 
Multiple linear regression (MLR) 
Partial least squares (PLS) regression 
Artificial neural network (ANN) regression  
Stepwise regression 
[39] 
[39] 
[66] 
[39] 
 
Some of these methods, e.g. RF, SVM and ANN, have been invented and implemented to handle 
both regression and classification problems [73]. Each method has its advantages and limitations in 
terms of e.g. computation time/memory, overfitting tendencies, sensitivity to noise and 
interpretability [69,72,73], and their predictive success depends on the nature of the training set and 
the types of chemical descriptors. The descriptor selection techniques and QSAR modeling methods 
are in some cases integrated, e.g. when applying GAs on MLR or SVM [76].  
QSARs built using the same training set may produce discrepant predictions for a query chemical due 
to differences in the applied statistical methods and/or chemical descriptor sets. Therefore, rather 
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than relying on a single prediction for a given endpoint for the query chemical, increased certainty in 
the prediction can be achieved by applying a consensus or battery approach (Figure 3, 3). In a 
consensus or battery approach, the predictions from the individual models are integrated to output 
one consensus or battery prediction. This approach is used on a large scale e.g. in the Danish (Q)SAR 
Database (see 2.2.3) [77,78]. In general, by combining multiple predictions to reach final 
battery/consensus predictions, a better and more correct description of the relationship between 
the query chemical structure and its predicted activity can be obtained due to the noise or limited 
coverage of the single model being canceled by the others [79]. 
2.2.1.4 Methods in Statistical Validation of QSAR Model 
After a model has been developed it should be statistically validated for its goodness-of fit, 
robustness and predictive performance within one or more defined ADs (see more in section 2.2.2). 
Here some of the most common methods in QSAR validation are briefly presented (Figure 3, 4). 
Goodness-of-fit 
The goodness-of-fit is a measure of the model’s internal performance, i.e. how well the model 
predicts its own training set. For classification models the goodness-of-fit is sometimes expressed as 
Cooper statistics [80], including sensitivity, specificity, concordance and balanced accuracy, which 
are calculated based on the confusion matrix (Figure 4).  
Confusion matrix 
QSAR Predictions 
Positive Negative 
Experimental values 
Positive True Positive (TP) False Negative (FN) 
Negative False Positive (FP) True negatives (TN) 
 
𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 =  𝑇𝑇
𝑇𝑇 + 𝐹𝐹 , the proportion of experimental actives correctly predicted 
𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 =  𝑇𝐹
𝑇𝐹 + 𝐹𝑇 , the proportion of the experimental inactives correctly predicted 
𝐵𝐵𝐵𝐵𝑆𝑆𝑆𝐵 𝐵𝑆𝑆𝑎𝑎𝐵𝑆𝑆 =  𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 + 𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆
2
 , the average of the sensitivity and specificity 
Figure 4: Confusion matrix and Cooper statistics. 
External validation 
External validation is part of model predictivity assessment and the procedure consists of predicting 
a test set, i.e. a set of substances not used for training the model. A robust external validation, i.e. 
made with a test set of sufficient size and structural diversity to be representative of the chemical 
diversity of the model’s training set, is by some scientists considered the ’gold standard’ to assess a 
model’s predictive performance (as discussed in [17]). The experimental data of the test set should 
 Part II  
29 
 
preferably be of the same type as the experimental results in the training set, i.e. in the ideal case 
tested following the same protocol and data analysis at the same laboratory and by the same 
personnel [35]. When the test set has been run through the model the predictions that fall within 
the defined AD are compared with the corresponding experimental data and different statistical 
measures can be calculated, e.g. the Cooper statistics (Figure 4).  
A limitation sometimes met by model developers is the absence of a test set. A test set can be 
acquired by: using part of the curated dataset, i.e. splitting; generating new experimental data; or 
finding new data in databases or the literature that is similar to the data in the training set. If the 
entire dataset has been used for model training and new data are not available, external validation is 
not possible. If the test set is acquired by splitting the experimental dataset into training and test 
sets, the splitting method is of importance [17]. Robust external validation with a test set from a 
rational splitting will likely result in more optimistic coverage and predictive performance estimates 
compared to the estimates from a test set made from random splitting [17]. The external validation 
results from a test set made with random splitting will generally give more realistic estimates of the 
model’s future screening set performance [40].   
Cross-validation  
Cross-validation is a common and popular technique used for assessing both model robustness and 
predictive performance. Cross-validation approaches include for example leave-one-out (LOO), 
leave-many-out (LMO), randomization, stratified randomization and bootstrapping. LOO is a type of 
k-fold cross-validation, which is a commonly used cross-validation method for QSAR models. Briefly, 
in k-fold cross-validation, the training set, S, is split into k subsets S1, …, Sk, where  
Ø,
11
==
==
1
k
i
i
k
i
i SSS  
In the LOO case, k is equal to the number of entries in the training set. The selected k is often 
dependent on the training set size, and regularly used k for robust cross-validations includes 2, 5, 10 
and 20 [17,36]. Then k cross-validation models, Mi, are built using S\Si, so that all k subsets have 
been included in all but one of the k cross-validation models. Each cross-validation model, Mi, which 
should be built without any transfer of information from the full parent model such as selected 
descriptors, is externally validated with the left-out subset, Si. The procedure can be made x times in 
a so-called x times k-fold cross-validation. The statistical results from the k external validations are 
averaged to give an overall statistics, which is then used as an estimate for the predictive 
performance of the parent model made on the full-training set, S (Figure 4). The variance in the 
individual cross-validation model performance measures, expressed as e.g. a standard deviation 
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(SD), can be used for estimating the robustness of the parent model. Large variability, i.e. high SDs, 
in the cross-validation model performance estimates indicate a parent model being easily affected 
by changes in the constitution of the training set.  
Some scientists criticize the use of cross-validation to assess model predictivity [81,82] as results 
from cross-validations have in some cases reported optimistic and misleading estimates. Such 
optimistic results are likely derived from cross-validations where either k has been too large, e.g. 
LOO on large training sets, or information from the full training set model has been transferred to 
the cross-validation models [65]. They may also be due to conservative measures derived from an 
external validation with uncritical use of a test set with experimental results that are not similar 
enough to the training set experimental results. A large systematic study that compared robust 
cross-validation, i.e. no reuse of information and appropriate sizes of k, with robust external 
validation has shown that robust cross-validation generally underestimated model predictivity [17].  
To summarize on the topic of statistical validation of QSAR models, a combination of robust external 
and cross-validation is likely the optimal, although not always a practical, choice when assessing the 
robustness and predictive performance of a model [39]. If part of the dataset has been used as a test 
set for robust external validation, this can have an effect on the developed model, which can suffer 
on both coverage and predictive performance of future screening sets [17] due to the resulting 
lower number of chemicals available for model training. To circumvent this in practice, the test set 
can be added to the training set and used for building a bigger model. In this case it is important to 
remember that the external validation results from the first model do not apply on the new bigger 
model. However, by comparing the results from the external validation with cross-validation of the 
first model, an indication can be obtained of whether the cross-validation procedure outputs 
realistic results or if it is either overoptimistic or conservative in its nature. This information can be 
taken into consideration when assessing the cross-validation results of the bigger models. A 
comparison of corresponding measures from the goodness-of-fit and the external- and/or cross-
validation can be made. If the statistical measures from the goodness-of-fit test are significantly 
larger than those from the external- and/or cross-validation, this indicates that the model has been 
overfitted to its training set and thus lost some of its ability to generalize. Overfitting may be due to 
inclusion of too many descriptors in the model, or it can be related to the model building method 
and its parameters [83].  
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2.2.1.5 QSAR Development using Leadscope Predictive Data Miner 
In this PhD project, the commercial QSAR modeling software Leadscope Predictive Data Miner 
(LPDM), a component of LeadScope®Enterprise Server6, was used for 2D QSAR development. The 
data collection, curation and preparation steps were made prior to the import of datasets into LPDM 
using programs such as Microsoft Excel and OASIS Database Manager [84]. OASIS Database Manager 
is a software platform that can store chemical structures as well as process and manage chemical 
information [84]. Here is a brief and more theoretical description of LPDMs QSAR development 
methods. More detailed descriptions on the practical use of LPDM in the PhD project are given in the 
respective project chapters in Part III. 
During the import of a dataset into LPDM, a set of nine molecular descriptors are automatically 
calculated for each structure: ALogP, Hydrogen Bond Acceptors and Donors, Lipinski Score, 
Molecular Weight, Parent Atom Number, Parent Molecular Weight, Polar Surface Area, and 
Rotatable Bonds. Additionally, a systematic substructure analysis is performed on each structure 
using a hierarchy of approximately 27,000 pre-defined 2D structural keys [51,52,85,86].  
When a training set has been successfully imported, model development can be started and consists 
of three main steps. In the first and optional step more descriptors can be added to the initial 
descriptor set prepared in the importing step, i.e. the pre-defined structural features and the 
calculated molecular descriptors. The new descriptors can come from the generation of predictive 
scaffolds from the current dataset, addition of previously generated dataset scaffolds or by 
importing descriptors from an external source. The scaffolds are created by assembling LPDM pre-
defined structural keys into larger substructures that are commonly occurring within a group of 
training set structures or that discriminate for the response variable [52,86]. In LPDM, the descriptor 
selection is divided into two phases: 1) a pre-selection of descriptors before model building, and 2) 
an iterative descriptor reduction during model building to optimize the number of descriptors and 
factors (i.e., latent variables) in the model [85].  
The second step of LPDM model development includes the phase 1) pre-selection of descriptors 
from the calculated molecular descriptors, pre-defined structural features and any added 
scaffolds/external descriptors using either automatic or manual selection. In LPDM’s automatic 
descriptor selection, all singletons and non-differentiating descriptors are first removed, and then a 
t- or X2-test is used to evaluate the influence of each descriptor on the continuous or binary 
response variable, respectively [85]. Then it selects the top 30% of the descriptors according to the 
X2-test for a binary response variable, or the top and bottom 15% according to the t-test for a 
                                                     
6 http://www.leadscope.com/ 
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continuous response variable. In the manual mode, the model developer selects the preferred 
descriptors for model building.  
After phase 1) descriptor pre-selection, the third and final LPDM model development step starts. In 
this step, LPDM builds a predictive model using PLS regression for a training set with a continuous 
response variable and PLR for a binary response variable [85,86]. In the PLS or PLR, the descriptors 
are used in factors that are extracted and rotated one at a time to maximize the correlation between 
a principal component and the response variable [85]. The default maximum number of factors is 10 
but the model developer can change this maximum or choose a fixed number of factors. In LPDM’s 
automated model building mode, a model is first built using all the phase 1) pre-selected descriptors. 
During model building, a k-fold cross-validation procedure is performed that outputs a predicted 
residual error sum of square (PRESS) and other statistical measures. The default size of k depends on 
the size of the training set but k can also be manually set by the model developer. The descriptors 
with low loading, low weight, and high residuals in the model are identified, and of these between 5 
and 25 are removed. The reduced descriptor set is used in a new model building and cross-validation 
round. This procedure is repeated until up to 15 predictive models have been built, and among these 
preliminary models the model with the lowest PRESS is selected as the final model.  
It is important to note that LPDM’s cross-validation method transfers information such as the 
selected descriptors from the full model to the smaller cross-validation models. This is therefore in a 
mathematical sense not a true cross-validation and due to the reuse of information the cross-
validation estimates have a tendency to be overoptimistic in its measures on model performance. 
Many other software tools for QSAR development exist, both commercially and freely available, 
including open-source. They use a wide variety of the descriptor sources, descriptor selection 
methods as well as QSAR modeling algorithms. Examples include SciQSAR, MultiCase CASE Ultra [77] 
as well as packages in MATLAB7, R8 and Python’s Scikit-learn9 [72]. An overview is available from the 
EU Antares project10. 
2.2.2 The OECD Principles for Validation of QSAR Models 
To facilitate the use of QSARs for e.g. regulatory purposes in the context of chemical hazard and risk 
assessment a need to harmonize the validation of QSAR models arose [1]. At the international 
workshop ‘Regulatory Acceptance of QSARs for Human Health and Environmental Endpoints’ held in 
2002 in Setubal, Portugal [87], six principles were proposed for assessing the validity of QSAR models 
[1]. Subsequently, an OECD (Organisation for Economic Co-operation and Development) Expert 
                                                     
7 https://se.mathworks.com/products/matlab.html 
8 https://www.r-project.org/ 
9 http://scikit-learn.org/stable/ 
10 http://www.antares-life.eu/index.php?sec=modellist 
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Group assessment of the principles resulted in two of the principles being merged into a single 
principle. This resulted in the adoption of five OECD principles for QSAR validation in 2004 [1,88,89]. 
Together, the five OECD principles focus on the scientific validity, i.e. relevance and reliability, of a 
model [1]. For a QSAR result to be adequate for regulatory use the estimate should be generated by 
a scientifically valid model that is applicable to the chemical of interest with the necessary level of 
reliability and whose endpoint is assessed relevant for the regulatory purpose [1]. For regulatory 
acceptance, the QSAR models and their validation, including the five OECD principles, should be 
documented in the QSAR Model Reporting Format (QMRF), and the individual QSAR predictions 
should be documented in the QSAR Prediction Reporting Format (QPRF) [1]. These two documents 
can be used by the authorities to assess whether the applied model is scientifically valid and fit for 
purpose, and if the prediction is reliable and adequate enough to be included in a chemical hazard or 
risk assessment [1]. Guidance on the principles has been described in several documents [1,88–91]. 
Here is a short introduction and discussion of the OECD QSAR validation principles:  
1. A defined endpoint 
This principle is intended to ensure clarity and transparency in the endpoint being predicted by the 
given model. Endpoint refers to any physico-chemical property, biological effect, or environmental 
parameter that can be measured and modeled. The nature and sources of the experimental data 
used in the training set have an influence on the reliability of the model. If data originates from 
multiple sources or varying testing/data analysis protocols, this can affect the model performance as 
these (small) variations will be built into the model. By providing adequate information on the 
endpoint, the model user can evaluate if the endpoint and the quality of the underlying data comply 
with his or her standards for the intended purpose. 
2. An unambiguous algorithm 
To ensure transparency in the description of the model algorithm with the purpose of having 
reproducible predictions, the QSAR model should preferably be expressed in the form of an 
unambiguous algorithm. Full transparency is often not possible when applying a commercial 
software or very complex model algorithms but in such cases a detailed description of the software 
and/or modeling process can be given to provide sufficient information for reproducing the model 
and predictions under the same conditions. 
3. A defined applicability domain 
A defined AD should be given to describe the limitations of the model in terms of the types of 
chemical structures, physico-chemical properties and mechanisms of actions for which the model 
can return reliable predictions. This principle is important to ensure that the QSAR model only makes 
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interpolations based on the information from its training set. Multiple AD definitions can be applied 
to the same model depending on its purpose and how reliable predictions the user/developer 
requires. Generally, a stricter AD results in models with smaller coverage but higher predictive 
performance as a consequence of excluding less reliable predictions [15,92]. However, this general 
rule depends on the training set and the method and definition used for AD and in some cases 
predictions outside the AD can be as accurate as the predictions inside the AD [79,92].  
4. Appropriate measures of goodness-of-fit, robustness and predictivity 
This principle covers the statistical validation of the QSAR models and the methods are introduced in 
section 2.2.1.4. In general, two types of statistical information are required to assess the model’s 
goodness-of-fit, robustness and predictive performance: a) an internal performance determined by 
predicting the training set; and b) an assessment of the model’s predictivity of a test set, i.e. a set of 
chemical structures never seen by the model. The goodness-of-fit serves to provide statistical 
information for a). The model predictivity statistics for b) can be derived from robust external 
validation and/or from robust cross-validation that will in addition provide information of model 
robustness.  
5. A mechanistic interpretation 
The intent of this principle is to ensure that any identified mechanistic association between 
descriptors used in the model and the model endpoint are documented. A mechanistic 
interpretation can further strengthen the confidence in the model established based on the previous 
four principles. It is not always possible to provide a mechanistic interpretation of a QSAR model 
however, and it is furthermore important to keep in mind that even if a strong correlation is found 
between descriptor(s) and the response variable this does not imply that there is causality. 
2.2.3 The Danish (Q)SAR Database 
The current version of the Danish (Q)SAR Database (http://qsar.food.dtu.dk/) was released in 
November 2015 and replaced the previous version from 2004. It is a free, online database with 
structural information, QSAR predictions, and in some cases experimental results, for ~640,000 
discrete organic chemical substances [78]. It is developed and maintained at the Technical University 
of Denmark (DTU) with support from the Danish Environmental Protection Agency (EPA) and Nordic 
Council of Ministers. More than 200 global QSAR models have been applied for around 45 endpoints 
covering physico-chemical properties, molecular mechanisms including mutagenesis and receptor 
binding, to in vivo and clinical endpoints. Most endpoints have been modeled in three different 
commercial QSAR systems: LPDM, Scimatics SciQSAR and MultiCASE® CASE Ultra [77]. The individual 
predictions from each system as well as a battery prediction call integrating the three predictions are 
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available. QMRFs for all the applied models are provided. The online database is capable of doing 
complex search queries, including substructure, similarity and property searches or combinations of 
these. The predictions in the Danish (Q)SAR Database can be used in for example screening, profiling 
and prioritization by industry, academia, agencies and NGOs. The database is dynamic and 
predictions from new models will continuously be added, for example predictions from the LPDM 
models developed in this PhD project. All predictions in the Danish (Q)SAR Database will be 
incorporated into the OECD (Q)SAR Toolbox [93], where the predictions together with other 
information can be used in constructing chemical categories for grouping and read-across purposes.  
Currently under development is a ‘sister-site’ to the Danish (Q)SAR Database. Here the in-house 
LPDM models from the Danish (Q)SAR Database, including the models developed in this PhD project, 
will be made available for free prediction of user-submitted structures. Besides predictions of 
structures not in the Danish (Q)SAR Database, users will have access to more prediction details such 
as analog structures from training sets and model structural features used to produce the 
predictions.  
2.2.4 Application of QSAR 
QSARs are used in multiple chemical research areas such as drug discovery and toxicology [2], and 
they are among other things applied to: 
• increase the amount of (toxicological) information on chemicals 
• help prioritize and rank chemicals/drugs for further testing or evaluation [94] 
• help the (medical) chemist optimize structures to a given target [31] 
• help design safer substitution chemicals 
• contribute to the reduction and replacement of animal testing [95]  
Furthermore, since a QSAR model averages over all the closest analogs in the training set, it is 
possible for an individual model estimate to be more accurate than an individual experimental 
measurement, and QSARs can in some cases cause identification of chemicals with erroneous 
experimental results [1,12,22]. Below are some examples on the application of QSAR. 
2.2.4.1 QSAR in Regulations 
The regulatory interest and use of QSAR is steadily increasing as they hold the potential to help fill 
the large gaps in toxicological information of the many thousands of man-made chemicals queued 
for risk assessment and classification and labeling [2,79,95–101]. Furthermore, QSAR results provide 
additional mechanistic information useful in for example grouping of chemicals into categories for 
read-across and improve evaluation of existing test data [1]. Multiple examples on the use of QSAR 
for replacement or supplement of experimental data in regulatory contexts exist for physico-
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chemical properties, environmental fate parameters and ecotoxicological endpoints [1,94,102–105]. 
For human health effects, however, the application of QSARs is still in its early phase [103] and has 
primarily been used as a supplement to experimental data and for groupings and prioritization 
purposes [1,94]. Facing forward, QSARs are expected to be used increasingly for direct replacement 
of test data as the experience in and acceptance of QSARs and their predictions become more 
widespread within the regulatory community [1,95].  
Examples of regulatory implementation of QSARs can be found in EU’s chemicals regulation, REACH 
[101], and  the International Council for Harmonisation (ICH) M7 guideline [100]. Briefly, the ICH M7 
guideline describes the approach to identify, categorize and control DNA reactive, mutagenic 
impurities in pharmaceutical products to limit the potential carcinogenic risk from such impurities 
[100,106]. Here (Q)SAR predictions from two complementary QSAR methodologies, i.e. a statistical-
based and an expert rule-based, followed by expert review may be used for classification of drug 
impurities in case of missing experimental data. The absence of structural alerts from the two 
complementary (Q)SAR methodologies is sufficient to conclude that the impurity is of no mutagenic 
concern, and no further testing is recommended [100]. 
2.2.4.2 QSAR in Screening and Prioritization 
QSAR models are useful tools for screening and prioritization of chemicals for further testing. For 
example QSARs can be used in a tiered screening approach where the most problematic chemicals 
or the most promising drug candidates based on QSAR predictions are prioritized for further in vitro 
and/or in vivo testing [1,62,94,107].  
The Danish EPA has for around two decades supported a number of activities on research and 
development as well application of QSARs for screening in regulatory contexts. For example, the 
Danish EPA together with QSAR researchers from the National Food Institute, DTU, has since 2001 
published four versions of the Advisory list for self-classification of dangerous substances [108–111]. 
In these projects, QSAR predictions for a number of endpoints of relevance for acute oral toxicity, 
skin sensitization and irritation, mutagenicity, carcinogenicity, reproductive toxicity (i.e. possible 
harm to the unborn child) and danger to the aquatic environment were used to make advisory 
classifications for ~33,835 EINECS (European Inventory of Existing Commercial Chemical Substances) 
substances according to the CLP-regulation (classification, labelling and packaging of substances and 
mixtures) criteria [96,109]. A second example is a Danish EPA supported project from 2013 that 
describes the use of QSAR to identify potential CMR (carcinogenic, mutagenic or toxic to 
reproduction) REACH substances according to the CLP-regulation [112]. Screening results from 
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QSARs have also recently been used by the Danish EPA for grouping a number of brominated flame 
retardants [113]. 
2.2.4.3 QSAR in Early Drug Development 
Because of the time and cost demanding process of bringing a new drug to the market and the high 
attrition rate [114,115], the pharmaceutical industry is striving towards implementation of 
technologies that can optimize the process [116]. The application of in silico methods for ligand-
based virtual screening (LBVS), including QSAR models, has become a routine tool in drug design and 
early drug discovery phases in some pharmaceutical companies [117,118]. QSARs are used for fast 
screening of large sets of virtual small-molecule drug candidates to identify activity towards the drug 
target as well as toxicological properties [62,119]. QSARs are also used by the medical chemist to 
identify chemical features involved in the drug target activity and this information can be used for 
optimizing and isolating drug candidates [31,118,120].    
2.2.4.4 QSAR in Hypothesis Generation 
If information for two or more different biological endpoints is available for a big and diverse set of 
chemicals, statistical correlations between the results from the endpoints can be calculated, and if a 
significant correlation is found this may be an indication of a biological association between the 
endpoints. The correlations can be performed using different methods such as univariate or 
multivariate data analysis. A number of papers using univariate data analysis for correlation studies 
between results from an array of HTS in vitro and an in vivo endpoint have been published [121] and 
can help researchers generate new hypotheses on associations between molecular mechanism(s) 
and effects at the organ/organism level. This data-driven inductive and holistic approach for 
hypothesis generation [122] holds the limitation of restrictions in the number of overlapping 
structures having experimental results in the studied endpoints. With QSAR models it is possible to 
generate information for multiple biological endpoints for a large and structurally diverse set of 
structures, which can then be used for performing statistical correlations [36,123] and generating 
new hypotheses. It is important to keep in mind that the associations are purely statistical and the 
generated biological hypotheses will need to be tested by applying other techniques.  
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2.3 Regulatory Toxicology 
Toxicology, from the ancient Greek words toxikos (“poisonous”) and logia (“study of”), is the study of 
adverse effects of chemical substances on living organisms and was founded as a research field by 
Paracelsus (1493-1541 CE) [1]. Today, it applies theories and methods from multiple disciplines such 
as biology, biochemistry and computer science to identify a chemical’s potential adverse effects, 
which is influenced by factors such as dosage, time and route of exposure, properties of the exposed 
organism (sex, age, health, etc.) as well as other environmental factors (simultaneous exposure to 
other chemicals, temperature, etc.).  
The production and diversity of man-made chemicals applied in industry, agriculture, war and 
consumer products are steadily increasing, and imprint of such chemicals can be found all over the 
world today [2,3]. Because of their potential adverse impact on human health and the environment, 
there is increasing concern about the safety of the chemicals in our surroundings. Chemicals are 
subject to different national and international chemical regulations that require different levels of 
toxicity information depending on their production volume, use, etc. [4–8]. A chemical risk 
assessment combines information from hazard identification/characterization and exposure 
evaluation [9]. Traditionally a chemical’s potential hazard(s) on human health are identified using 
standard animal (i.e., in vivo) toxicity testing of apical endpoints such as cancer [9–11]. In some 
cases, a serious hazard of a chemical such as it being CMR can result in restrictions irrespective of 
exposure level and use [10,12]. In most cases, however, the hazard characterization and subsequent 
risk assessment and classification and labeling of chemicals is more complex [7,12]. 
2.3.1 A Paradigm Shift in Toxicology  
For the majority of the man-made chemicals none or only limited toxicity data are available [13,14], 
and use of classical regulatory toxicology in vivo tests to fill the large data gaps of the many 
thousands chemicals queued for risk assessment is practically impossible due to time and economic 
limitations [10,13,15–21]. Also, the ethically problematic animal toxicity studies do not always 
translate well to humans [22,23] and provide limited information on the actual mechanism(s) 
underlying the adverse outcome(s) [10,16,17,24,25]. To meet these challenges, regulatory toxicology 
has called for a paradigm shift to identify, develop and apply more sustainable and practical testing 
and non-testing methods that ultimately can replace animal testing [16,17,26–28]. Facing the 
challenge, the U.S. EPA together with the National Toxicology Program (NTP) asked the National 
Research Council (NRC) to develop a long-range vision and strategy for future toxicity testing, which 
resulted in the publication of the game-changing report from 2007 entitled ´Toxicity Testing in the 
21st Century: A Vision and a Strategy´ [16,17]. Here it is discussed how technological advances in 
molecular biology and computer science during the 20th and continuing into the 21st century can 
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help scientists identify cellular and molecular mechanisms in ‘toxicity pathways’ that may lead to 
adverse outcomes. The report envisions that understanding of chemical interaction with molecular 
mechanisms in ‘toxicity pathways’ can be used to reliably predict toxicity in a cost- and time-efficient 
way while reducing animal use and suffering [16,17,28].  
Today, ten years after the report was released, agencies, academia and industry are continuously 
taking new initiatives to meet the paradigm shift. For example, new test and non-test methods are 
developed or optimized. HTS in vitro assays use either cell-free systems or cell-lines, preferably of 
human origin, to identify chemical interaction with mechanisms in ‘toxicity pathways’ [29–31]. The 
rationale is that a battery of such HTS in vitro assays can be used as a tool to identify and prioritize 
chemicals that should progress to further, more resource-demanding toxicological evaluation 
[30,32]. However, testing new sets of chemicals in medium- or high-throughput in vitro assays can 
also be costly and time-consuming due to the many ‘toxicity pathways’ molecular mechanisms that 
need to be covered and testing at multiple concentrations [33,34]. In addition, for some of these in 
vitro assays, use of animals is a necessity to get hold of the cell cultures [35]. Development and use 
of non-test methods, such as QSAR, to screen and prioritize chemicals for further testing can serve 
as a pre-filter for HTS testing [20,21,36] or be applied directly or indirectly (i.a., in groupings/read 
across methodology) to fill data gaps [7]. The alternative methods, both in vitro and in silico, have 
already resulted in an ocean of data and lead to questions on how to best handle, assess and 
recognize the limitations of this data [37]. Linking mechanistic data from alternative methods to 
adverse outcomes at the organism or population level is another challenge being faced [37]. The 
regulatory system has not fully adapted to the use of mechanistic data from alternative methods but 
still mainly relies on animal toxicity data. Furthermore, regulators, who have been trained to make 
decisions based on apical endpoint data from animal studies, may be unfamiliar with and uncertain 
about the interpretation of this new type of data, which further limits its potential use in chemical 
risk assessment.  
As chemical risk assessments combines knowledge on the hazardous potential of the given chemical 
with its level of exposure and use, another major challenge in risk assessment is to estimate the 
human exposure levels of the many thousands chemicals in our surroundings [13,38–42]. Also, 
current chemical risk assessment is based on the exposure and hazards associated with a single 
chemical but humans and wildlife are exposed to complex mixtures of natural and man-made 
chemicals, which may act through multiple ‘toxicity pathways’ and can cause additive or synergistic 
toxicity effects [43,44]. Parallel to the challenge of filling data gaps on toxicity and exposure levels 
for individual chemical substances, is the challenge of how to test and risk assess chemical mixtures 
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[45]. The exposure and mixture effect challenges and some suggested methods to address these are 
discussed elsewhere [43,45–47] and will not be further elaborated in this thesis. 
2.3.2 ToxCast and Tox21 Programs 
To face the challenge of filling the toxicity data gaps for the many thousands of man-made 
chemicals, the U.S. EPA National Center for Computational Toxicology (NCCT) launched the Toxicity 
Forecaster research program, known as ToxCast11, in 2007 with the overall aim to ”use in vitro HTS 
approaches to support the development of improved toxicity prediction models” (cit. from [37]) 
[24,37,48,49]. ToxCast is the U.S. EPA contribution to the Toxicity in the 21st Century (Tox21) 
program, which was initiated in 2008 as a U.S. federal ‘multiagency’ collaboration among the U.S. 
EPA, the Food and Drug Administration (FDA) and National Institutes of Health (NIH), including the 
National Center for Advancing Translational Sciences (NCATS) and the NTP at the National Institute 
of Environmental Health Sciences (NIEHS) [50,51]. Tox21 was a response to the NRC report ‘Toxicity 
Testing in the 21st Century: A Vision and a Strategy’ [16,17,27], which calls for a collaborative effort 
across the toxicology community to rely less on animal studies and more on in vitro tests using 
human cells and cellular components to identify chemicals with toxic effects. Although ToxCast and 
Tox21 share the same overall aims [37,48,52,53], they apply different approaches. In Tox21 the 
focus is on testing a large chemical inventory of around 10,000 substances (the full Tox21 set, 8,193 
unique chemicals) in a small selection of HTS assays each year [24,53], while in ToxCast an EPA 
selected subset of the Tox21 chemicals, currently 3,726, are tested in many hundreds of assays to 
cover multiple ‘toxicity pathways’ [37,51,54]. 
The ToxCast chemical library consists of structurally diverse man-made compounds such as 
plasticizers, pesticides, phthalates, antimicrobials and food additives as well as approved and failed 
drugs [24,25,37]. The ToxCast program is being conducted in multiple phases. Phase I was completed 
in 2009 as a ‘Proof of concept’. In this phase 310 unique chemicals, mainly pesticides with 
accompanying animal toxicity data, were screened for approximately 700 HTS assay endpoints 
[24,37,49]. Next, ToxCast Phase II was initiated and includes 293 reprocured Phase I chemicals, a 
subset of 768 chemicals considered to have the highest priority of the EPA Tox21 set, as well as 799 
unique chemicals, known as the ‘Endocrine 1000’ or E1K set [37]. The Phase II chemicals are 
screened for  around 900 assay endpoints, including most of the original approximately 700 
endpoints from Phase I, with the exception of the E1K set, which is screened only in a limited subset 
of Phase II endocrine-related assays [37]. In late 2014, ToxCast Phase III was started with new 
                                                     
11 https://www.epa.gov/chemical-research/toxicity-forecasting 
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technologies and endpoints added, as well as including a new set of ~1900 unique EPA selected 
Tox21 chemicals of regulatory concern [36,37].  
The inclusion criteria and procurement of EPA’s Tox21 subset inventory, which currently consists of 
3,726 chemicals, are described in [37]. All chemicals have undergone thorough quality reviews [55], 
and the chemical structures have undergone a standardized and validated procedure to produce EPA 
‘QSAR-ready’ structures [37,56]. The assays in ToxCast and Tox21 are a compilation of biochemical 
assays, cell-based assays, complex culture assays and small animal models, and most of these were 
originally applied by the pharmaceutical industry [24,50]. The NIH NCATS high-throughput robotic 
screening system is used on some of the commercial assays [37]. A subset of the assays has been 
developed by U.S. EPA or NIH scientists as part of the ToxCast/Tox21 program [24,35,57,58]. Most 
assays were run in medium or high-throughput concentration-response for all chemicals [24], and in 
general assay data are considered to be of high quality and reproducibility [35,50,53,57]. In some 
cases, a tiered screening approach is applied, where the chemicals are first tested at a single high 
concentration, and chemicals exceeding a defined endpoint activity threshold are prioritized for 
concentration-response testing [57,58]. The raw concentration-response ToxCast data from different 
sources are processed through a U.S. EPA customized data analyzing pipeline in R12, which results in 
a final ‘hit-call’ for each chemical-assay-endpoint [37,59]. A ‘hit-call’ of 1 (active) or 0 (inactive) for a 
chemical is based on a decision on whether a statistically significant concentration-response is 
modeled and takes into account outliers and general toxicity data such as cytotoxicity [59]. The full 
Tox21 dataset is processed through another but similar data analyzing pipeline by NIH [53,60,61].  
Besides the Tox21/ToxCast programs other sources of HTS in vitro data exists. PubChem13 is a free, 
online database from NIH National Center for Biotechnology Information (NCBI) that provides 
structural information for millions of chemical structures and data on biological activities of small 
molecules [62]. Part of the ToxCast and Tox21 data are available from PubChem. Other similar online 
databases include ChEMBL14, BindingDB15, ChemProt16 and CTD17.  
The data used in project 3.1 are from ToxCast, and project 3.4 data originate from ToxCast and 
Tox21 assays. The data in project 3.2 were from NIH NCATS but on another chemical collection 
called NCGC (NCATS Chemical Genomics Center), which consists primarily of drugs [63,64]. The 
models in projects 3.1, 3.2 and 3.4 were all developed in close collaboration with the data providers. 
                                                     
12 https://www.r-project.org/about.html  
13 https://pubchem.ncbi.nlm.nih.gov/  
14 https://www.ebi.ac.uk/chembldb/ 
15 http://www.bindingdb.org/bind/index.jsp 
16 http://potentia.cbs.dtu.dk/ChemProt/ 
17 http://ctdbase.org/ 
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In project 3.3, data were curated from the PubChem database [62]. More information on the data 
can be found in the respective project chapters. 
2.3.3 Adverse Outcome Pathways 
As mentioned earlier, the use of mechanistic data from alternative methods, such as the ToxCast 
and Tox21 HTS in vitro data, in a regulatory toxicology context has faced multiple challenges [11,24]. 
To meet the challenge of how to link mechanistic results from alternative methods to adverse 
effects at the organism or population level, OECD initiated the development of AOPs in 2012 [65]. 
The AOP framework is an expansion of NRCs ‘toxicity pathways’ [16,17] and the Mode-of-Action 
(MoA) concept  (Figure 5) [66–68], and it aims to simplify complex biological systems by relating 
molecular mechanisms to adverse effects in a one-way scheme. Descriptions of biological pathways 
is not a new concept, but has been made by scientists for decades. The novelty in the AOP 
framework is to systematize, standardize and simplify the pathways to make them useful in a 
regulatory context. 
Figure 5. The AOP framework 
An AOP endeavors to make a simple representation of existing knowledge concerning causal 
linkages between an MIE and a cascade of intermediate key events (KEs) at subcellular, cellular, 
tissue and/or organ levels that lead to a specific adverse outcome (AO) at individual or population 
level (Figure 5) [10,66,69]. An AO can be explained by multiple AOPs in a so-called AOP network [70], 
just as an MIE or a KE may be included in several AOPs with different AOs [11]. The AOP conceptual 
framework provides the biological context to alternative data with the objective to make e.g. 
regulators more familiar with and confident in the use of mechanistic data from alternative methods 
in e.g. WoE assessments or integrated testing strategies (ITS) for chemical risk assessment. Also, 
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well-constructed AOPs can help identify where existing testing or non-testing approaches can 
facilitate regulatory decision making, and drive development of new key in vitro assays and in silico 
models [10,11]. Furthermore, information from AOPs can be used in the design and refinement of in 
vivo experiments to get as much relevant information out of the animals used. The ultimate and 
long-term regulatory goal of the AOP framework is to replace animal toxicity testing of a chemical 
with alternative methods for effects on MIEs and/or KEs levels.  
In 2014, OECD in collaboration with the U.S. EPA, the U.S. Army Engineer Research & Development 
Center (ERDC) and the European Commission (EC) Joint Research Center (JRC) launched the AOP 
Knowledgebase (KB)18. The AOP-KB integrates four individually developed platforms to more 
effectively allow stakeholders to develop, review and comment on AOPs. The AOP-Wiki19, developed 
by the U.S. EPA and EC JRC, is one of the platforms in the AOP-KB and serves as a central repository 
for all AOPs under development. The AOPs in the AOP-Wiki are dynamic and at different stages in 
their development. In addition, OECD with financial support from the EC have developed 
Effectopedia20, an open-knowledge and structured online platform able to display quantitative 
information in AOPs.  
2.3.4 Integrated Approaches to Testing and Assessment 
In addition to the AOP initiative, OECD introduced the IATA concept [71] to assist in the paradigm 
shift within regulatory toxicology [67]. In IATA a defined question regarding a chemical’s (or a group 
of chemicals) hazard identification, characterization or risk assessment is answered by taking a 
systematic and iterative approach to integrate existing information from multiple methodologies 
and techniques, including QSAR, read-across, toxicogenomics, in vitro and in vivo, with the 
identification of data gaps and a judicious generation of new data [10,67]. The main benefits 
expected from the use of IATAs include reduction, refinement and replacement of animal testing 
(i.e. the 3Rs), more cost-effective and efficient testing and assessment as well as the generation of 
more extensive and reliable data [67].  
An IATA can range from the more flexible and less formalized judgement-based approaches to the 
more structured and rigid rule-based approaches that leaves little or no room for expert choices 
[10,67,72,73]. The choice of IATA depends on the specific decision-making and its context. Overall, 
existing and new data are continuously used in a WoE assessment to inform regulatory decisions and 
when an acceptable level of information is met, a final regulatory decision can be reached. The IATA 
decision procedure integrates gathered information on a chemical’s exposure level/use, ADME 
                                                     
18 http://aopkb.org 
19 https://aopwiki.org 
20 https://effectopedia.org 
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(absorption, distribution, metabolism and excretion) and toxicity in a WoE assessment approach to 
reach the decision on the endpoint of concern (Figure 6).  
The AOP concept can be included in an IATA to provide the biological rationale in the decision 
making and to identify MIEs or KEs for which methods and data exist or for which new testing or 
non-testing methods are desirable [10,74]. If existing testing, e.g. HTS in vitro assays, or non-testing, 
e.g. QSARs, methods are available for an MIE/KE these can be used for generating new data to 
inform the IATA. In cases where in vitro assays or QSARs are missing/unavailable for an MIE/KE 
assessed to be relevant in the AOP-based IATA, the development of new testing and non-testing 
methods may be initiated (Figure 6).  
Figure 6. Illustration of an AOP-based IATA 
2.3.5 Registration, Evaluation and Autorisation of CHemicals 
The EU chemical legislation, REACH, was put into force in June 2007 [7,75] to ensure the safe use of 
chemicals with minimal risk for humans and the environment as well as to promote the 
development of alternatives to animal testing and enhance innovation and competiveness in the 
industry [7]. One of the key principles in REACH is that the responsibility for demonstrating the safe 
use of chemicals lies with the industry/registrants [76]. Multiple deadlines for the registration of 
substances under REACH have been set since its implementation in 2007 with the final registration 
deadline in June 2018 for the lowest tonnage substances, i.e. less than 10 tonnes per year. The 
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registration deadlines have put pressure on the industry/registrant to collect the necessary toxicity 
data for the more than 70,000 anticipated registrations [19,77]. While applying a precautionary risk 
assessment approach, REACH is also cutting edge in the use of alternative testing and non-testing 
methods for regulatory purposes. In Articles 13 and 25 of REACH it is clearly stated that vertebrate 
testing should only be performed as a last resort after considering all other options such as gathering 
all existing information available on the substance, including information from alternative methods 
such as in vitro methods and (Q)SARs [7].  
The minimum toxicity testing requirements for a registered substance under REACH depends on the 
quantity of the substance manufactured or imported into EU in tonnes per year, with higher 
requirements the higher the quantity [7]. The standard information requirements for the different 
tonnages are described in Annexes VII to X of REACH [7]. QSARs can potentially be used to meet 
standard information requirements at all tonnages levels if they are assessed adequate for the 
specific purpose. Overall, (Q)SAR results can be used instead of testing for regulatory purposes when 
the following conditions are met: 1) the results are derived from a scientifically valid (Q)SAR model 
following the OECD validation principles (see section 2.2.2), 2) the predicted substance falls within 
the QSAR model’s AD, 3) the predictions are assessed to be adequate for the purpose of 
classification and labelling and/or risk assessment, and 4) adequate and reliable documentation on 
the applied model is provided [76]. These conditions are best documented in QMRF and QPRF. If 
some of the information elements in the conditions are missing or are inadequate, the (Q)SAR 
predictions may still be used in a WoE assessment approach in e.g. in an AOP-informed IATA [10,76]. 
At quantities of 10 or more tonnes per year the chemical substance has to be evaluated for 
reproductive toxicity according to the standard information requirements listed in Annex VIII to X 
[7]. In 2014, the extended one-generation reproductive toxicity study (EOGRTS) [78] replaced the 
two-generation reproductive study in column 1 of point 8.7.3 of Annexes IX and X [7,79] and was 
included in the EU test method regulation amendment [80]. DNT testing using e.g. cohort 2A/2B in 
EOGRTS is only required in REACH in case of serious concerns [7,18]. Triggers of such concerns are 
currently being identified in a close collaboration between the European Chemicals Agency (ECHA), 
member states and stakeholders and should result in a guidance document [81]. Suggestion for such 
triggers could be evidence from alternative methods on chemical interaction with MIEs or KEs in 
AOPs for DNT outcomes [10], for example some of the thyroid-related AOPs under development 
[10,82–86].  
Endocrine disruption represents another potential gap in REACH requested dossier information (as 
well as other EU regulations) [18]. On June 15th 2016, the EC published a draft on its long-waited 
and debated criteria for the identification of EDCs in a Communication together with an impact 
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assessment report setting out the criteria implications on regulations and their implementations 
[87,88]. The criteria have been criticized by politicians, scientists, NGOs and a number of member 
states, including Denmark, to be too weak to protect humans and the environment against adverse 
effects from EDCs [89,90]. 
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3.1 QSAR Models for TPO Inhibition In Vitro 
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Abstract 
Thyroperoxidase (TPO) is the enzyme that synthesizes thyroid hormones (THs). TPO inhibition by 
chemicals can result in decreased TH levels and developmental neurotoxicity, and therefore 
identification of TPO inhibition is of high relevance in safety evaluation of chemicals. In the present 
study, we developed two global quantitative structure-activity relationship (QSAR) models for TPO 
inhibition in vitro. Rigorous cross- and blinded external validations demonstrated that the first 
model, QSAR1, built from a training set of 877 ToxCast chemicals, was robust and highly predictive 
with balanced accuracies of 80.6% (SD = 4.6%) and 85.3%, respectively. The external validation test 
set was subsequently merged with the training set to constitute a larger training set totaling 1,519 
ToxCast chemicals for a second model, QSAR2, which underwent robust cross-validation with a 
balanced accuracy of 82.7% (SD = 2.2%). An analysis of QSAR2 identified the ten most discriminating 
structural features for TPO inhibition and non-inhibition, respectively. Both models were used to 
screen 72,524 REACH substances and 32,197 U.S. EPA substances, and QSAR2 with the expanded 
training set had approximately 10% larger coverages compared to QSAR1. Of the substances 
predicted within QSAR2’s applicability domain, 8,790 (19.3%) REACH substances and 7,166 (19.0%) 
U.S. EPA substances, respectively, were predicted to be TPO inhibitors. A case study on butyl 
hydroxyanisole (BHA), which is used as an antioxidant, was included to exemplify how predictions 
from the developed QSAR2 model may aid in elucidating the modes of action in adverse outcomes of 
chemicals. Overall, predictions from QSAR2 can for example be used in priority setting of chemicals 
and in read-across cases or weight-of-evidence assessments. 
Keywords 
QSAR; thyroperoxidase (TPO) inhibition; Adverse Outcome Pathway (AOP); Screening; BHA; REACH;  
Abbreviations 
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1. Introduction 
Thyroid hormones (THs) participate in multiple biological processes from early development and 
throughout adulthood [1–3]. In the fetus and neonate, THs play an essential role in 
neurodevelopment [4], where they are involved in neuron differentiation, proliferation and 
migration, dendritic branching and synaptogenesis, and myelination [1,5]. In early gestation, the 
fetus depends entirely on maternally-derived THs until the fetal thyroid gland becomes functional at 
approximately gestational week 12 in humans and gestational day 17-18 in rats [1,6,7]. Maternal THs 
continue to contribute to fetal TH levels throughout gestation in both humans and rats [1,6]. Studies 
have shown that even a moderate and transient decrease in maternal TH levels during pregnancy is 
associated with permanent adverse neurological changes in the offspring [8]. In animal models and 
humans altered cognition, socialization, and motor function as well as hearing loss have been 
observed following moderate to severe hypothyroidism [6,9–17]. Even low levels of TH insufficiency 
during fetal development may result in measurable IQ deficits in children [9,13–18]. In adulthood, 
dysregulated TH levels can give reversible clinical symptoms of hypo- or hyperthyroidism [8] and are 
correlated with pathological processes involved in adverse outcomes such as cancer, obesity and 
type II diabetes mellitus [19,20].  
Humans are exposed to tens of thousands of man-made chemicals through food, drugs, air, water 
and consumer products [21–24]. Large data gaps exist for most of these xenobiotics on their 
potential thyroid disrupting properties [25]. Xenobiotics can disturb TH homeostasis through many 
different mechanisms, including altered TH synthesis, transport, metabolism, and receptor activation 
as well as disruption of the HPT axis [10,25–28]. The same xenobiotic may act through more than 
one mechanism [25].  Because of the severity of the adverse effects that can be expected from 
chemical disruption of thyroid homeostasis, especially during early development, there is a need to 
develop a strategy for the identification and testing of thyroid-active compounds. As a step towards 
replacing expensive and time-consuming whole animal studies with alternative methods in chemical 
risk assessments, the Organisation for Economic Co-operation and Development (OECD) launched a 
new program on the development of Adverse Outcome Pathways (AOPs) in 2012 [29]. An AOP 
describes the sequential chain of causally linked events at different levels of biological organization 
starting from a so-called molecular initiating event (MIE) going through a number of downstream 
linked key events (KEs), and ends at an adverse health or ecotoxicological effect [29,30]. According 
to the OECD, AOPs are the central element of a toxicological knowledge framework to support 
chemical risk assessment based on mechanistic reasoning. AOPs can help industry and regulators use 
results from alternative methods, such as in vitro and in silico methods, in chemical risk assessments 
[31], e.g. by applying the AOP in OECDs Integrated Approaches to Testing Assessment (IATA) context 
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[29,32,33]. Multiple thyroid-related AOPs have been suggested [34,35]. One AOP under 
development determined to have a strong overall weight-of-evidence describes a series of linked 
events from the MIE, thyroperoxidase (TPO) inhibition, leading to hypothyroxinemia, and resulting in 
altered neurodevelopment and neurological dysfunction in the offspring [41, see also 4 and 19]. TPO 
is a heme-containing multifunction enzyme essential in TH synthesis [37,38]. Recently, a high-
throughput screening (HTS) in vitro assay for TPO inhibition was developed by the U.S. 
Environmental Protection Agency (EPA) National Center for Computational Toxicology (NCCT) [39] 
and used to screen 1,126 ToxCast Phase I and II chemicals including structurally diverse 
environmental chemicals and failed drugs [34,40,41]. The assay is based on microsomes from rat 
thyroid tissue and requires the amount from approximately one rat to assess quantitative TPO 
inhibition of 1.5 chemicals [39]. An additional set of 771 ToxCast chemicals (known as the ‘Endocrine 
1000’ or ‘E1K´ set) [41,42] was subsequently screened in the same HTS TPO inhibition assay 
(Simmons et al., in prep).  
The goal of the present study was to use the ToxCast data to develop in silico models, and apply the 
models to large inventories of man-made chemicals to predict their potential to inhibit TPO. For this 
purpose, we first used experimental TPO inhibition results for 1,126 ToxCast Phase I and II chemicals, 
including replicated samples, to prepare a training set of 877 unique chemicals, which was then used 
to train and cross-validate a global binary Quantitative Structure-Activity Relationship (QSAR) model. 
QSARs are mathematical models that relate chemical structure descriptors with an experimental 
continuous (e.g. EC50) or categorical (e.g. positive/negative) activity. Once established, these in silico 
models can be used as a non-testing approach to predict the activities of untested chemical 
structures (an introduction to QSAR can e.g. be found in [43] and [44]). The E1K dataset was used to 
prepare a test set of 646 chemicals, which was applied to externally validate the QSAR model. Next, 
the test set was merged with the training set to form a larger training set of 1,519 unique chemicals, 
which was subsequently used for training and cross-validating a second QSAR model. An analysis of 
the structural features in the second QSAR model was performed to identify features that best 
discriminated TPO inhibitors from non-inhibitors. Both QSAR models were used to screen two large 
EU and U.S. chemical inventories containing man-made substances potentially present in e.g. the 
environment and consumer products for their possible TPO inhibition activity. The screened EU 
inventory consists of 72,524 REACH pre-registered substances (PRS) structures extracted from the 
online Danish (Q)SAR Database structure set [45,46]. Briefly, REACH pre-registration concerns 
existing substances that companies plan to register under REACH, the EUs chemicals regulation, as 
so-called phase-in substances. The U.S. inventory was originally curated by the U.S. EPA as a part of 
the CERAPP project [47] and contains 32,464 unique structures to which humans are potentially 
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exposed. The structures were curated from sources such as the ACToR CPCat database [21], the 
DSSTox database [48], the Canadian Domestic Substances List, the Endocrine Disruption Screening 
Program set and EPI Suite training and test sets [41,42,47]. Predictions from these screenings will  
inform a tiered approach to prioritize possible thyroid modulating chemicals for further evaluation 
and could be used, together with relevant AOP(s), in IATA weight-of evidence (WoE) risk 
assessments [29,33,49]. We also conducted a case study to highlight how the developed QSAR 
models for TPO inhibition can support hypotheses regarding the mode of action for chemical-
induced adverse outcomes observed in in vivo studies. 
2. Materials and Methods 
2.1 Experimental Datasets 
We used two datasets provided by U.S. EPA NCCT with chemical structure information and HTS 
screening results for TPO inhibition in vitro to train and validate two QSAR models. The chemicals 
screened contained diverse chemical structures including environmental and industrial chemicals as 
well as some failed drugs [41]. The chemicals in both datasets were not selected specifically for this 
project or based on suspected TPO inhibition activity, and the original datasets include internal 
replicated samples. The experimental results consisted of data from the HTS Amplex®UltraRed-
thyroperoxidase (AUR-TPO) in vitro assay [39], which had further undergone a selectivity filtering 
procedure to identify potentially false positive results due to non-specific activity decrease in the 
AUR-TPO assay [34]. Briefly, all chemical structures were initially screened at a single, high 
concentration (~87.5µM). The chemicals associated with 20% or greater decreases in maximal TPO 
activity were subsequently screened for possible concentration-response. The concentration-
response data were processed as described previously using the ToxCast data pipeline whereby each 
chemical was assigned a ‘hit-call’ of 1 if active in AUR-TPO, or a ‘hit-call’ of 0 if inactive in AUR-TPO 
[50]. Actives in the AUR-TPO assay were further processed through a selectivity filtering algorithm, 
which integrates results from cytotoxicity and luciferase inhibition assays to identify possible non-
specific positive results in the AUR-TPO assay [34]. The chemical structures, assays, data analysis and 
selectivity filtering procedure have been described in more details previously [34,39,40,50]. We 
classified the chemicals into three categories: 1) chemicals that had a <20% activity decrease in the 
single, high concentration screening, or had been assigned a ‘hit-call’ of 0 in the concentration-
response AUR-TPO screening were classified as inactive in this assay; 2) chemicals with a ‘hit-call’ of 
1 in AUR-TPO and a selectivity score greater than 1 were classified as active for TPO inhibition; and 
3) chemicals with a ‘hit-call’ of 1 in AUR-TPO but with a selectivity score of 1 or less were classified as 
inconclusive for TPO inhibition.  
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The first dataset provided to the QSAR model developers at the National Food Institute (Food), 
Technical University of Denmark (DTU), consisted of structure information and experimental results 
for 1,126 ToxCast Phase I and II chemicals [34,40,41], including replicates, and was used for 
preparing a training set referred to as training set 1 (Figure 1). The second E1K dataset of an 
additional 771 chemicals from ToxCast [41,42], initially containing only structural information, was 
used for preparing a test set for external validation of the selected QSAR model build from training 
set 1 (see 2.3) (Figure 1). After determining the external validation statistics, the experimental 
results of the test set structures were made available to the model developers at DTU Food. The test 
set and training set 1 were then merged to form a second, larger training set referred to as training 
set 2 (Figure 1).  
 
Figure 1. An overview of the datasets, modeling, structural feature sorting and screening. Here µ equals x ̄ in 
the text and is the mean TPO inhibition experimental activity and n is the number of training set structures. 
2.2 Structure Preparation 
All chemical structures in the two U.S. EPA NCCT provided datasets had previously undergone an 
extensive quality control and structure curation procedure as part of the ToxCast program [41,51]. 
The QSAR software applied in this study handles organic chemical structures with an unambiguous 
2D structure. We apply an overall definition of structures acceptable for QSAR processing in all our 
in-house QSAR software [45,46], as structures:  
• containing at least two C atoms 
• containing only the atoms H, Li, B, C, N, O, F, Na, Mg, Si, P, S, Cl, K, Ca, Br, and/or I; and, 
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• that are not mixtures consisting of two or more organic components  
The structures that did not fulfill these criteria were removed from the two datasets. Further 
processing of the structural information included stripping off ions and neutralization of the organic 
parent structures, i.e. all structures were used in their non-ionized form.  
Next, identical QSAR-ready structures within the first dataset were identified and their assigned 
experimental results were compared. For identical structures with concordant activities, only one of 
the structures was kept. If a group of identical structures had discrepant activities then the whole 
group was removed from the dataset. Next, structures with inconclusive experimental results, i.e. 
‘hit-call’ of 1 in AUR-TPO and a selectivity score of 1 or less, were removed and the dataset now 
constituted training set 1 (Figure 1). The same duplicates removal procedure was performed by U.S. 
EPA NCCT scientists on the DTU Food experimentally-blinded E1K set, which then constituted the 
test set (Figure 1). Some of the QSAR-ready structures in the test set were identical to structures in 
training set 1 and were therefore excluded from the external validation. When the test set 
experimental results were made available to DTU Food, and training set 2 was prepared by merging 
the test set and training set 1 (Figure 1), the experimental results of the identified structural 
duplicates were compared. Again, if they had concordant experimental result only one of the 
structures was kept, while all the structures were removed in case of disagreement between the 
experimental results. 
2.3 QSAR Modeling and Selection 
We used the commercial software Leadscope® Predictive Data Miner (LPDM), a component of 
Leadscope® Enterprise Server version 3.2.4 [52], to build the QSAR models. Briefly, for each chemical 
structure in a training set LPDM automatically performs a systematic sub-structural analysis using a 
template library of more than 27,000 pre-defined structural features and calculates nine molecular 
descriptors (AlogP, Hydrogen Bond Acceptors and Donors, Lipinski Score, Molecular Weight, Parent 
Atom Number, Parent Molecular Weight, Polar Surface Area, Rotatable Bonds) [53]. The structural 
features and molecular descriptors are included in a default descriptor set. In addition, the user may 
call a functionality in LPDM to generate and add new training set-dependent structural features 
(scaffolds) to the descriptor set. The pre-defined structural features, added scaffolds and numeric 
molecular descriptors are included in an initial descriptor set. From the initial descriptor set, an 
automatic descriptor selection procedure in LPDM selects the top 30% descriptors according to 
Yates X2-test for a binary response variable. For the current training set 1 and 2 with  binary 
response variables, predictive models were built using partial logistic regression (PLR) with further 
selection of descriptors in an iterative procedure, and selection of the optimum number of PLR 
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factors based on least predictive residual sum of squares. LPDM has the option of building 
composite models, a type of ensemble models, for training sets with an imbalanced distribution of 
actives and inactives. With this option a number of sub-models are created by specifying the desired 
ratio of actives to inactives per sub-model training set, so that each of the sub-models contains the 
smaller class and a sample of the bigger class. The positive prediction probability (see 2.4) for a 
query chemical from a composite model is defined as the average of the positive prediction 
probabilities of all sub-models having the test chemical in the applicability domain (AD) [54]. 
Multiple modeling approaches were applied in LPDM to build seven predictive models for TPO 
inhibition first using training set 1 (Figure 1):  
1) single (i.e., non-composite) 
2) single with scaffolds 
3) single with scaffolds and a reduced set of structural features 
4) composite 
5) composite with scaffolds 
6) composite with scaffolds and a reduced set of structural features 
7) composite model combining model 3 and the sub-models from model 6  
In 1 and 4, the descriptors were selected among the default descriptors, i.e. the molecular 
descriptors and the predefined structural features, and used to build a single model and a composite 
model, respectively. Next, scaffolds were generated in LPDM for the training set structures and 
added to the initial descriptor set, which subsequently was used for descriptor selection for models 
2 and 5. In models 3 and 6, the scaffold-enriched descriptor set was reduced using a built-in function 
in LPDM (i.e., ‘Remove most features – (removes less similar features)’) that removed certain similar 
structural features before the descriptor selection. This step was employed to achieve a higher-
quality set of fewer structural features, eliminate highly similar or redundant ones, and reduce the 
risk of overfitting. In model 7, the single model 3 and the sub-models from composite model 6 were 
combined to constitute a new composite model with equal weight of all its sub-models.  
During model building all seven models underwent a ten times two-fold cross-validation by the 
LPDM algorithm. The algorithm transfers knowledge of the selected descriptor set from the parent 
model when building the cross-validation models, and we therefore do not use it for our measures 
of absolute predictive performance, but only to guide relative performance-based selection between 
the seven preliminary models. Among the seven predictive models built from training set 1, we 
selected the model with the highest performance from the LPDM cross-validation for further 
validation and screening studies (Figure 1). The selected model, called QSAR1, was then closed for 
further development (Figure 1). 
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2.4 Applicability Domain Definition 
The definition of the AD applied in this project consists of two components: 1) the definition of a 
structural domain in LPDM, and 2) a DTU Food in-house class probability refinement on the output 
from LPDM:  
1) For a test compound to be within LPDM’s structural domain it was required that: all molecular 
descriptors used in the model could be calculated, it contained at least one structural feature used in 
the model, and it had at least 30% Tanimoto similarity with a training set compound [54]. The 30% 
Tanimoto similarity was a default cut-off in the LPDM software. For a test compound outside this 
structural domain no prediction call (active/inactive) was generated by LPDM. For test compounds 
within the LPDM structural domain, a positive prediction probability, p, between 0 and 1, was given 
together with the prediction call; actives having a p ≥ 0.5 and inactives having a p < 0.5 [54].  
2) To exclude less reliable predictions, i.e. those with a positive prediction probability close to the 
cutoff p = 0.5, we required p ≥ 0.7 for active prediction calls and p ≤ 0.3 for inactive prediction calls. 
Predictions within the LPDM structural domain but with an associated positive prediction probability 
in the interval 0.3 to 0.7 were thus defined as outside of the AD and excluded from the statistical 
analyses. 
2.5 Validation of the Models 
Next, the closed QSAR1 model underwent an external validation blinded to DTU Food using the test 
set to evaluate its predictive performance (Figure 1). U.S. EPA NCCT compared the DTU Food 
generated test set prediction calls within the AD (see 2.4) with the corresponding experimental 
results and calculated sensitivity, specificity, balanced accuracy and coverage. Sensitivity is the 
percentage of experimental actives correctly predicted, specificity is the percentage of the 
experimental inactives correctly predicted, and balanced accuracy is the average of the sensitivity 
and specificity [55]. The coverage is the proportion of test set compounds that had predictions 
within the model’s AD.  
The assigned experimental activities for the test set were then made available to DTU Food, who 
merged the test set with training set 1 to constitute the larger training set 2 (see 2.2). Training set 2 
was used to build seven predictive models using the same modeling and LPDM cross-validation 
approaches described for training set 1 in 2.3, and of these the best performing model was selected 
(Figure 1). The selected model, called QSAR2, was closed for further development. 
As described above, the LPDM cross-validation algorithm was, due to the issue with transfer of 
knowledge to the cross-validation models, only used to guide the selection of the best performing 
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model among the seven models built from training set 1 and 2, respectively. The two selected and 
closed models, QSAR1 and QSAR2, were each subsequently subjected to a DTU Food in-house five 
times two-fold stratified cross-validation procedure to further estimate their robustness and 
predictive performance (Figure 1). This was done by randomly removing 50% of the structures from 
the training set, preserving the ratio of actives and inactives. Then a cross-validation model was built 
on the reduced training set using the same modeling approach as the full, parent model, but without 
transferring any established information such as selected descriptors from the parent model. The 
cross-validation model was applied to predict the 50% of the training set that had been removed. 
Likewise, a cross-validation model was made using the removed 50% of the training set, and this 
model was used to predict the remaining 50%. This procedure was performed five times resulting in 
ten cross-validation models. Sensitivity, specificity and balanced accuracy were calculated for the in-
AD predictions for each of the ten cross-validation models, and the mean and standard deviation 
(SD) were computed to give overall statistical measures of the predictive performance and 
robustness of the parent model based on the full-training set. The coverage, i.e. the mean 
percentage of how many of the predicted substances that had predictions within the AD of the ten 
cross-validation models, was also calculated. 
2.6 Structural Features in QSAR2 
To identify structural features in QSAR2 related to TPO inhibition or non-inhibition, respectively, all 
features in the model were sorted in descending order by: 
    |0.5 − ?̅?| ∙ 𝑆  
where n is the number of training set 2 structures containing the given feature, and x ̄ is the mean 
TPO inhibition experimental activity (1 for actives and 0 for inactives) of the n training set structures.  
With this metric the QSAR2 structural features that discriminate well between the two classes, i.e. 
actives and inactives, and are contained in the largest number of training set 2 structures are given 
the highest ranking. Based on this sorting, the top ten structural features with an x ̄ ≥ 0.8, i.e. 
structural features associated with activity, and an x ̄≤ 0.02, i.e. structural features associated with 
inactivity, respectively, were identified (Figure 1). The cutoff of x ̄≤ 0.02 was chosen instead of 0.2, 
which would have been symmetric to the x ̄≥ 0.8 cutoff for activity associated structural features, 
due to the larger proportion of inactive structures in the training set.  
2.7 Screening Large Chemical Inventories 
The structures in the REACH-PRS inventory were originally curated from deliverable 3.4 of the 
OpenTox EU project and had previously been processed through the structure preparation steps 
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described in 2.2 [56]. The 72,524 QSAR-ready REACH-PRS structures included structural duplicates, 
and the REACH-PRS set thus contained a total of 60,281 unique structures (Figure 1). The U.S. EPA 
inventory was also previously processed through the structure preparation steps described in 2.2 
and 32,197 unique QSAR-ready structures remained. Both the REACH-PRS set and the U.S. EPA set 
were screened through the QSAR1 and QSAR2 TPO inhibition models to identify substances with the 
potential to inhibit TPO. We applied both QSAR1 and QSAR2 to be able to assess the effect of adding 
the test set structures to training set 2 with regard to the coverages of the two inventories and the 
prevalences of predicted TPO inhibitors. While QSAR2 is likely to provide better coverages of the 
inventories, the lack of an external validation of QSAR2 may for some purposes suggest that QSAR1 
is a more appropriate model. The overlaps in substances as well as unique structures between U.S. 
EPA and REACH-PRS were identified (Figure 1). The proportion of the QSAR-predicted U.S. EPA and 
REACH-PRS substances within the AD of QSAR1 and QSAR2 and the activity distributions of the 
predictions were calculated.  
3. Results and Discussion 
This is to our knowledge the first study to develop global binary QSAR models for TPO inhibition and 
apply them to predict two large and structurally diverse chemical inventories containing man-made 
substances for their TPO inhibiting potential.  
3.1 The Training and Test Sets 
The number of QSAR-ready structures and the distribution of active and inactive experimental 
results in training set 1, the test set and training set 2 are summarized in Table 1 (will be made 
available in a supplementary file for submission). The numbers given in Table 1 reflect the situation 
after removing structures that were either unsuited for QSAR processing in the applied software, 
structural duplicates or had inconclusive experimental results. In training set 1 this resulted in the 
removal of 72 structures due to structural QSAR criteria, i.e. structures inacceptable for QSAR 
processing, 21 due to structural duplicates (four of these due to conflicting experimental results), 
and 156 due to inconclusive experimental results; in total 249 out of the 1,126 initial structure 
entries. In the external validation test set, a total of 125 out of the 771 initial E1K structure entries 
were removed; 14 due to structural QSAR criteria, 23 due to overlap with training set 1 structures, 
14 due to internal structural duplicates (two of these due to conflicting experimental results), and 74 
due to inconclusive experimental results. When merging training set 1 and the test set, which at this 
point was un-blinded to DTU Food, the experimental results of the 23 structures removed from the 
test set due to overlap with training set 1 structures were compared with their corresponding 
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training set 1 experimental results. In four cases the experimental results disagreed, and these 
structures were therefore removed from the final training set 2 (Table 1). 
Table 1. Number of structures in the QSAR-ready training sets 1 and 2, and test set with the distribution of 
active and inactive experimental results for TPO inhibition. 
Datasets Total number of unique structures Active (%) Inactive (%) 
Training set 1 877 130 (14.8) 747 (85.2) 
Test set* 646 100 (15.5) 546 (84.5) 
Training set 2** 1519 230 (15.1) 1289 (84.9) 
*The experimental results of the test set were masked to DTU Food model developers until after being predicted in QSAR1. ** some of the 
training set 1 structures were tested again together with the test set structures, and of these four structures had different activities 
compared to the training set 1 activity. The four training set 1 structures were removed from training set 2. 
The chemical structures in the provided datasets had undergone thorough quality control and 
curation [41,51]. In addition, since the datasets originated from the same source, i.e. U.S. EPA NCCT, 
and all chemicals had been screened in the same testing protocols and undergone the same data 
processing, this has likely contributed to a decrease in the experimental variability. The data in 
training set 1 and 2 and the test set where therefore assessed to be of high quality [34,39] and 
expected to be a good basis for QSAR model development. The quality of the AUR-TPO assay has 
been assessed previously [34,39], which indicated excellent performance and intralaboratory 
repeatability (rZ’ from 0.77 to 0.83 and rCV of 3–4%). The AUR-TPO assay measures the fluorescence 
intensity from the commercial peroxidase substrate, Amplex®UltraRed (AUR), which is converted to 
Amplex UltroxRed by a peroxidase in the presence of hydrogen peroxide. A decrease in fluorescence 
intensity in response to a chemical is an indirect measure of TPO inhibition. The reaction chemistry 
and oxidation product of AUR is proprietary and the exact reaction(s) inhibited and its reversibility 
cannot be identified [34]. Therefore, the AUR-TPO assay read out has multiple potential 
confounders, including: non-specific enzyme inhibition; reactive, autofluorescent or fluorescence 
quenching chemicals; and other sources of interference with the peroxidase reaction [34,39]. When 
comparing results from the AUR-TPO assay with results from the lower throughput orthogonal 
guaiacol oxidation assay, the AUR-TPO assay was previously found to have a sensitivity of 86% and a 
specificity of 39% [34]. Part of the high sensitivity of AUR-TPO could be due to a higher rate of false 
positive results from confounding non-specific activity decrease, a known problem with loss-of signal 
assays. Identification and removal of such potentially AUR-TPO false positive TPO inhibitors in the 
datasets was attempted by the application of the selectivity score filter [34] and the inconclusive 
category, i.e. AUR-TPO positives with a selectivity score less than 1, see section 2.1. However, not all 
mechanisms potentially causing non-specific activity decrease, e.g. fluorescence quenching, have 
been addressed in the selectivity score [34] and so the presence of false positive TPO inhibitors in 
the training and test sets cannot be excluded. Furthermore, the tiered screening approach in AUR-
TPO with a cutoff of 20% activity decrease in the initial single, high-concentration screening [34] may 
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have produced some false negatives as it cannot be excluded that a portion of the chemicals causing 
an activity decrease below the cutoff would have been positive if screened for concentration-
response. In addition to the potential confounding effects in the raw experimental outputs, the 
models applied for the ‘hit-call’ assignment and the selectivity score algorithm are also subject to 
some degree of uncertainty in their results.  
3.2 QSAR Modeling and Selection 
Table 2 shows the LPDM cross-validation results for the seven models built from training set 1 and 2, 
respectively. As mentioned above, the LPDM cross-validation was used to guide relative 
performance-based selection between the seven preliminary models. As can be seen in Table 2, the 
composite models 4 to 7 outperformed the single models 1, 2 and 3 in the LPDM cross-validation 
with regard to the balanced accuracy (Table 2). This is most likely an effect of the imbalanced 
distribution of actives and inactives in both training sets with a ratio of approximately 1:6 (Table 1). 
The composite model option in LDPM was implemented to handle such imbalanced training sets to 
include also a high proportion of the bigger class and thereby optimize the size of the AD [54].  
Table 2. The results from the LPDM cross-validation of the seven built models from training set 1 and 2, 
respectively. 
Model  LPDMs 10 times two-fold cross-validation results 
Training set 1 Sensitivity (%) 
Specificity 
(%) 
Balanced 
accuracy (%) TP
* FP* TN* FN* 
1 43.0 96.8 69.9 49 21 626 65 
2 48.2 96.0 72.1 55 26 621 59 
3 50.0 96.3 73.2 57 24 623 57 
4 72.9 82.7 77.8 94 105 502 35 
5 81.4 78.2 79.8 105 136 498 24 
6 84.5 80.3 82.4 109 123 502 20 
7 74.6 92.5 83.6 97 55 676 33 
Training set 2 Sensitivity (%) 
Specificity 
(%) 
Balanced 
accuracy (%) TP
* FP* TN* FN* 
1 46.5 96.9 71.2 99 40 1153 114 
2 49.8 96.1 73.0 106 46 1147 107 
3 46.5 96.7 71.6 99 39 1154 114 
4 79.1 79.9 79.5 182 233 928 48 
5 75.7 79.5 77.6 174 240 931 56 
6 76.1 78.4 77.3 175 253 918 55 
7 71.3 92.6 82.0 164 95 1187 66 
*TP: true positives, FP: false positives, TN: true negatives, FN: false negatives. The numbers are averages of the ten iterations as given by 
LPDM. 
In this work we employed a new approach where a single, unbalanced model (i.e., model 3) was 
added as a sub-model, together with the balanced sub-models from a composite model (i.e., model 
6), to form a new composite model (i.e., model 7). This addition caused a significant reduction in the 
number of false positive (FP) predictions produced in the LPDM cross-validation as compared to 
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model 6 alone (see Table 2). For both training set 1 and 2 this resulted in a remarkable increase in 
the LPDM cross-validation specificity while causing a smaller reduction in sensitivity (Table 2), and 
together this explains why model 7, in both cases, outperformed the other composite models 4, 5 
and 6. To conclude, model 7 was the best performing among the seven models for both training set 
1 and 2, and therefore selected for both training sets, and these models were named QSAR1 and 
QSAR2, respectively (Table 3). 
Table 3. Modeling approach applied and the predictive performances for QSAR1 and QSAR2. 
*A five times two-fold cross-validation, ** A blinded external validation with the experimental results of the test set being masked to the 
model developers at DTU Food. 
3.3 Predictive Performance of the QSAR Models 
The two selected and final models, QSAR1 and QSAR2, underwent a five times two-fold DTU Food in-
house cross-validation procedure to evaluate their predictive performance and robustness. QSAR1 
also underwent a DTU Food blinded external validation with the test set. The results from the 
validation studies are presented in Table 3 and demonstrate high predictive performance, i.e. 
balanced accuracies of 85.3% by external validation for QSAR1 and 82.7% by cross-validation for 
QSAR2, respectively.  
Adding the test set to training set 1 to build QSAR2 served multiple purposes. One purpose was to 
explore how much the added test set would enlarge the AD of the model and thereby increase the 
coverages of the two large chemical screening inventories, U.S. EPA and REACH-PRS. The coverage of 
QSAR2 was roughly 6% larger in the cross-validation (Table 3) and 10% larger for both screening 
inventories (Table 5) than the respective coverages of QSAR1. A second purpose of adding the test 
set in QSAR2 was to explore the possible improvements in predictive performance. To do this, we 
first built the smaller QSAR1 model and performed both a rigorous five times two-fold cross-
validation procedure and a large external validation with the test set. As can be seen in Table 3 the 
validation procedures show that QSAR1 has high predictive performance and is a robust model, i.e. a 
balanced accuracy of 85.3% in external validation and 80.6% with an SD of 4.6% in the cross-
validation. A comparison of the statistical parameters from the two validation methods indicates 
that the rigorous cross-validation procedure applied does not overestimate the model’s predictive 
Model Statistical Parameter Cross-Validation*, % 
(SD, %) 
External Validation**, % 
(actual numbers) 
QSAR1 
Approach 7 
Sub-models: 7 
Sensitivity 72.3 (10.1) 79.7 (47/(47 + 12)) 
Specificity 89.0 (2.8) 90.8 (266/(266 + 27)) 
Balanced accuracy 80.6 (4.6) 85.3 ((79.7 + 90.8)/2) 
Coverage 51.6 (4.7) 54.5 (352/646) 
QSAR2 
Approach 7 
Sub-models: 7 
Sensitivity 75.6 (5.0) - 
Specificity 89.8 (1.5) - 
Balanced accuracy 82.7 (2.2) - 
Coverage 57.8 (5.4) - 
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performance, but rather, outputs conservative estimates. This conservative nature of the cross-
validation is likely due to the rigorous procedure of removing 50% of the full training set to build the 
cross-validation models. Such a procedure is especially hard on the proportionally few actives in 
training set 1, i.e. 130 out of 877 (Table 1), which is also reflected in the relatively high SD of 10% in 
the sensitivity of the ten QSAR1 cross-validation models as well as its lower mean value (72.3%) 
compared to the sensitivity from the external validation (79.7%) (Table 3). The structures in the test 
set used for the DTU-blinded external validation of QSAR1 were not selected due to specific TPO 
inhibition concerns or to serve as a representative test set for QSAR1, but instead selected because 
they are included in the U.S. EPA regulatory ToxCast universe based on potential for exposure, and 
not because of prior concern about endocrine disruptive effects [41,42].  
The procedure of performing both independent and robust cross-validation and a large, 
representative and prospective external validation is optimal when evaluating a model’s predictive 
performance, but external validation has the disadvantage of withholding what may be valuable 
data from the model itself. Adding all available data to a training set can, in addition to expanding 
the AD, also result in a model with a higher predictive performance, depending on the characteristics 
of the added data. The QSAR2 model could not undergo an external validation procedure due to lack 
of another external test set. Previous studies have shown that robust cross-validations give reliable 
estimates of a model’s predictive performance (e.g. [57,58]). This, together with the results from the 
cross-validation vs. external validation results of QSAR1, suggests that the applied cross-validation 
procedure can be used for assessing QSAR2’s predictive performance. Due to the conservative 
nature of the two-fold cross-validation, we anticipate that QSAR2 will have a similar or higher 
predictive performance if it underwent a large external validation with a test set generated using the 
same protocol and data processing. As can be seen from Table 3, the cross-validation sensitivity was 
slightly increased in QSAR2 (75.6%) compared to QSAR1 (72.3%) and the sensitivity SD was reduced 
from 10.1% to 5%. This is most likely the effect of an increase in actives from 130 in training set 1 to 
230 in training set 2, which renders the 50% exclusion in the cross-validation procedure less 
influential on the sensitivity. As there were already many inactives in training set 1, the addition of 
more inactives to training set 2 did, as expected, not have the same high impact on the specificity, 
which went from 89.0% (SD = 2.8%) in QSAR 1 to 89.8% (SD = 1.5%) in QSAR2.   
3.4 Top Structural Features in QSAR2 
The ten most frequent and discriminating predictive structural features associated with actives and 
inactives, respectively, in QSAR2 are shown in Figure 2. Among the highest ranking structural 
features associated with activity were versions of phenols, anisole and aniline. The most frequent 
 Part III  
80 
 
structural features associated with inactivity included ethers, esters, aryl halides and a tertiary 
amine. To our knowledge structural docking or pharmacophore studies for TPO have not been 
performed (Simmons et al., in prep). 
13/0 
benzene, 1,3-
dihydroxy- 
13/2 
 
 
 
 
 
Scaffold 288 
11/1  
benzene, 1-alkyl-
,4-amino(NH2)- 
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0/35 
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Figure 2. The structural features used in QSAR2 were sorted on |0.5 - x ̄(TPO inhibition activity)|∙ n, and the ten 
most frequent and discriminating structural features alerting for activity(x ̄(TPO inhibition activity) ≥ 0.8) and 
inactivity (x ̄(TPO inhibition activity) ≤ 0.02) are shown here. Ak matches saturated carbon and X matches the 
halogen atoms Cl, Br, I or F. Numbers in the upper left corners display the ratio of TPO inhibitors/non-
inhibitors in training set 2 for the specific structural feature. 
3.5 The Screening Results 
We found a total of 27,444 substances present in both the U.S. EPA and the full REACH-PRS 
inventories. There were 19,279 unique structures in common in the two inventories (Table 4). To our 
knowledge this is the first study that has quantified the overlap between these two inventories, both 
with regard to overall substances and unique structures. The high overlap between the U.S. EPA set 
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and the REACH-PRS set was not surprising since both inventories represent collections of man-made, 
environmental chemicals in the U.S. and EU, respectively.  
Table 4. The overlap in substances and unique structures between the U.S. EPA and REACH-PRS inventories.  
Overlap analysis U.S. EPA* 
REACH-
PRS** 
Total 
number 
In common Unique to a set 
REACH-PRS 
in U.S. EPA 
U.S. EPA in 
REACH-PRS 
REACH-
PRS U.S. EPA 
Structure 
entries 32,197 72,524 104,721 27,444 19,279 45,080 12,918 
Unique 
structures 32,197 60,281 92,478 19,279 19,279 41,002 12,918 
*U.S. EPA: QSAR-ready structures from an U.S. EPA selected inventory of man-made chemical structures to which humans are potentially 
exposed, ** REACH-PRS: QSAR-ready structures from the REACH pre-registered substances list 
Both the U.S. EPA and REACH-PRS inventories were screened using QSAR1 and QSAR2 for TPO 
inhibition. In Table 5 the coverage of the two substance inventories, i.e. the proportion of the full set 
predicted within the AD of the model, and the number of active and inactive predictions are 
presented for each model. As mentioned earlier, the coverages of QSAR2 was as expected larger 
than QSAR1 of both screening sets. The percentage of chemicals in the two inventories with active 
predictions in the AD of the two models ranged from 16.5% to 19.3% (Table 5), which was slightly 
higher than the percentage of experimentally determined actives of 14.8% to 15.5% in the training 
and test sets (Table 1).  
Table 5. The coverage (AD) and the number of active/inactive predictions of the U.S. EPA and REACH-PRS 
inventories in QSAR1 and QSAR2. 
  QSAR 1 QSAR2 
 Total In AD (%) 
Active 
(%) 
Inactive 
(%) 
In AD 
(%) 
Active 
(%) 
Inactive 
(%) 
U.S. EPA* 32,197 16,898 (52.5) 
2855 
(16.9) 
14,043 
(83.1) 
19,392 
(60.2) 
3201 
(16.5) 
16,191 
(83.5) 
REACH-PRS** 72,524 38,661 (53.3) 
7,128 
(18.4) 
31,533 
(81.6) 
45,540 
(62.8) 
8,790 
(19.3) 
36,750 
(80.7) 
REACH-PRS 
unique 60,281 
32,334 
(53.6) 
5,879 
(18.2) 
26,455 
(81.8) 
37,784 
(62.7) 
7,166 
(19.0) 
30,618 
(81.0) 
*U.S. EPA: QSAR-ready structures from an U.S. EPA selected inventory of man-made chemical structures to which humans are potentially 
exposed, ** REACH-PRS: QSAR-ready structures from the REACH pre-registered substances list 
As mentioned earlier, the chemicals in the experimental datasets were not selected on the basis of 
expected TPO inhibition effects. It is not known to what extent these slightly higher percentages of 
TPO inhibitors in the two predicted screening sets are due to FP predictions or if they reflect a true 
TPO inhibitor prevalence. The validation studies showed that both QSAR1 and QSAR2 have 
specificities >10% higher than their respective sensitivities (Table 3), and therefore both models are 
expected to, in a balanced universe, make relatively more FN than FP predictions.  
3.6 Butylated Hydroxyanisole as a Potential Thyroid Hormone Disruptor 
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2-tert-Butyl-4-hydroxyanisole (2-BHA)          3-tert-Butyl-4-hydroxyanisole (3-BHA)*                  
                                                                  
 
 
 
 
 
 
  
          
We searched the two chemical inventories for possible examples of human-relevant chemicals with 
known indications for adverse neurodevelopmental outcomes. Included in both the U.S. EPA and the 
REACH-PRS set were the two isomers of butylated hydroxyanisole (BHA, CASN 25013-16-5), 2-tert-
Butyl-4-hydroxyanisole (2-BHA, CASN 88-32-4) and 3-tert-Butyl-4-hydroxyanisole (3-BHA, CASN 121-
00-6) (Figure 3). 
BHA is manufactured and/or imported to the EU in a total of 100-1,000 tonnes per year and is used 
as an antioxidant and preservative in e.g. food, food contact materials, cosmetics, and 
pharmaceuticals [59–61]. It is an anticipated human carcinogen [62] and is has been noted to have 
published evidence of  developmental neurotoxicity (DNT)  in mammals [63,64]. Both in vitro and in 
vivo published studies indicate that the BHA isomers have endocrine-modulating potential, with 
most evidence for estrogenic and androgenic effects [61,65–70]. Based on this, BHA is on both the 
EU list of potential endocrine disruptors [71,72] and on the SIN (Substitute It Now!) List [73,74]. 
However, more data is needed to fully elucidate BHA’s potential as an endocrine disruptor and its 
mode of action(s) in DNT [61].  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. The two isomers of BHA and the three predictive structural features alerting for activity in QSAR2 
selected based on highest |0.5 – x(̄TPO inhibition activity)|*n and an x ̄≥ 0.8. *3-BHA (CASN 121-00-6) was 
included in the training set and is the closest analog to 2-BHA (CASN 88-32-4). 
Both 2- and 3-BHA were predicted active for TPO inhibition by QSAR2, and 3-BHA was included in 
the QSAR2 training set as a TPO inhibitor. Studies in rats and pigs indicate that exposure to BHA 
(mixture of the two isomers) in utero can cause effects such as changed T4 serum levels, altered 
thyroid gland function and histology, and altered brain weight and behavior in the offspring  
9/2 
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[64,65,70]. TPO inhibition is as mentioned above identified to be the MIE in an AOP for thyroid-
related neurodevelopmental adverse effects (under development) [41]. The three common top 
activity-associated structural features from QSAR2 in the two isomers were identified as described in 
2.6 and are shown in Figure 3. Two of the features, “Scaffold 297” and “benzene, 1-alcoxy-,4-
hydroxy” were among the top ten structural features associated with activity in QSAR2 (Figure 2). 
“Scaffold 297” was present in eleven training set 2 structures of which nine were experimentally 
active for TPO inhibition. The “benzene, 1-alcoxy-,4-hydroxy” structural feature was present in five 
training set 2 structures that were all experimentally active.    
The QSAR2 training set including flags for the test set structures of QSAR1 will be made available in 
the supplementary material. Work is underway to make the training sets available from the U.S. EPA 
ToxCast website. Furthermore, predictions for around 640,000 structures in QSAR2, including the 
72,524 REACH-PRS structures, will be made available from the online Danish (Q)SAR Database [46]. 
QSAR2 will also be made available for prediction of user-submitted structures in a coming free 
online Danish (Q)SAR Models sister-site to the Danish (Q)SAR database at the DTU homepage [46].  
4. Conclusions 
The present study reports the development, validation, and application of two global, binary 
composite QSAR models for TPO inhibition in vitro. The first model, QSAR1, showed high predictive 
performance in both cross-and external validation with balanced accuracies of 80.6% (SD = 4.6%) 
and 85.3%, respectively. QSAR2, the second model enlarged with the external test set of QSAR1, 
showed improved robustness and predictive performance in cross-validation compared to QSAR1, 
i.e. a balanced accuracy of 82.7% (SD = 2.2%), and this was largely driven by an increase in sensitivity 
from 72.3% (SD = 10.1%) of QSAR1 to 75.6% (SD = 5.0%) of QSAR2. The top-ten structural features in 
QSAR2 related to TPO inhibition and non-inhibition, respectively, were identified. The two QSAR 
models were used to screen two large chemical inventories from the U.S. and EU containing 
structurally diverse man-made chemicals to which humans are potentially exposed. QSAR2 showed 
an increase in coverage of around 10% for both inventories relative to QSAR1, and of the substances 
predicted within QSAR2’s AD, 8,790 (19.3%) REACH-PRS substances and 7,166 (19.0%) U.S. EPA 
substances, respectively, were predicted to be TPO inhibitors. Among the predicted TPO inhibitors 
were the two isomers of BHA, which have previously been shown to cause both TH and neurological 
effects in animal studies. These QSAR predictions may contribute to elucidating the mode of action 
by which BHA results in these altered TH levels and neurological outcomes. Overall, predictions from 
the two models can be used to prioritize chemicals for further testing in considerations of possible 
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concerns for downstream adverse outcomes (e.g., DNT) [75,76]. They may also be used e.g. in read-
across cases or in IATA WoE assessments.   
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3.3 QSAR Models for AhR Activation In Vitro 
3.3.1 Study Report 
 
A pilot study to explore the effect of rational selection of training set inactives on model 
predictive performance and coverage using a large imbalanced AhR activation dataset 
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Abbreviations: AD, applicability domain; AhR, aryl hydrocarbon receptor; AOP, Adverse Outcome 
Pathway; CYP, cytochrome P450; ER, estrogen receptor; FN, false negative; FP, false positive; HAH, 
halogenated aromatic hydrocarbons; HTS, high-throughput screenings; LPDM, Leadscope® Predictive 
Data Miner; MIE, molecular initiating event; PAH, polycyclic aromatic hydrocarbons; qHTS, 
quantitative HTS; QSAR, quantitative structure-activity relationship; SULT, sulfotransferase; TH, 
thyroid hormone; TN, true negative; TP, true negative; UGT, UDP-glucuronosyltransferase  
1. Introduction 
With the recent advances in in vitro assay technologies, data from high-throughput screenings (HTS) 
for molecular and cellular responses are becoming more and more common in public databases such 
as the PubChem database21 [1,2]. Such HTS datasets are often large, i.e. they can contain up to 
100,000s of samples tested, and tend to be highly imbalanced towards many inactives [2,3]. 
Previously, data shortage has been one of the main limiting factors for developing robust global 
quantitative structure-activity relationship (QSAR) models. The availability of large but highly 
imbalanced HTS datasets for molecular and cellular responses to chemicals has introduced new 
challenges when building global QSARs [2,3]. The datasets with 100,000s of entries are generally too 
large for most QSAR software to handle in a computer- and time-efficient way, and the very 
imbalanced distribution of actives to inactives poses a problem for many training algorithms. One 
solution is therefore to select a subset to be used for QSAR training, e.g. with the aim of building 
models with good predictive performance and/or high coverage of future prediction sets. 
Suggestions on subset sampling and mining of large imbalanced HTS datasets have been published 
previously [2–4]. The predictive performance of a QSAR, i.e. how good it is at making correct and 
reliable predictions, is strongly influenced by the quality of the underlying experimental data and 
structures on which it has been trained [5,6]. For global QSARs, the size and balance of the training 
set, the distribution of training set structures in the chemical space as well as the definition of an 
applicability domain (AD) also play a role in a model’s estimated predictive performance. Model 
coverage, also defined as the AD size, is the proportion of a prediction set for which the QSAR model 
can make predictions within the reliability established in the QSAR validation. Addition of structures 
to a training set can enhance the model’s coverage and predictive performance, and the degree of 
coverage and predictive performance improvement will most likely depend of the number of 
structures added as well as their effect on the chemical space covered by the training set. 
The aryl hydrocarbon receptor (AhR) is a ligand-dependent transcription factor that regulates the 
expression of genes, whose products are involved in multiple biological processes such as 
metabolism of endogenous and exogenous small molecules as well as regulation of organ 
development and the immune system [7]. Due to its wide and important biological involvement, AhR 
                                                     
21 https://pubchem.ncbi.nlm.nih.gov/  
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continues to be a popular research area22. Some of the best-characterized exogenous AhR ligands 
include dioxins, halogenated aromatic hydrocarbons (HAHs) and nonhalogenated polycyclic aromatic 
hydrocarbons (PAHs). Further studies have identified a structurally-diverse group of chemicals as 
AhR agonists [7]. Some of the genes regulated by AhR encode enzymes involved in phase I and II 
metabolism of exogenous as well as endogenous compounds. The two AhR-regulated cytochrome 
P450 (CYP) subtypes, CYP1A1 and CYP1B1, are among other things involved in phase I metabolism of 
estrogens [8–10]. AhR also regulates the expression of sulfotransferase (SULT) and UDP-
glucoronosyltransferase (UGT) isoenzymes that are important in the catabolism of e.g. thyroid 
hormones (THs) and estrogens [11–13]. Thus exposure to man-made chemicals that interact with 
AhR can through upregulation of enzymes such as CYPs, UGTs and SULTs result in altered turnover of 
endogenous hormones and hereby potentially interfere with normal physiology and lead to adverse 
health effects. One example is given in an Adverse Outcome Pathway (AOP) (under development) 
that describes how the molecular initiating event (MIE) of chemical interaction with AhR upregulates 
TH catabolism and leads to reduced TH levels and can result in adverse neurodevelopmental 
outcomes [14]. AhR can also modulate the responsiveness of various hormone receptors [7]. Best 
understood is the cross-talk with the estrogen receptors (ERs), whose activity can be repressed by 
ligand-activated AhRs through sequestering of common co-activators/factors [7]. Similar types of 
cross-talk between AhR and other nuclear receptors and transcription factors are likely [7].  
Due to the involvement of AhR in toxic responses to chemicals such as reduced TH levels and 
neurodevelopmental adverse outcomes [14], it is of high relevance to be able to identify and 
characterize chemical structures that activate AhR. A number of HTS in vitro assays for AhR 
interaction have been developed and applied to screen thousands of small molecules [15,16]. Such 
data have previously been used in the development of QSAR models for AhR activation, e.g. QSAR 
models developed from Tox21 HTS data under the Tox21 challenge in 2014 [15]. In the present 
study, a large PubChem dataset with 324,858 chemical structures probing the classical AhR-gene 
activation mechanism in a quantitative HTS (qHTS) in vitro assay was curated and used to prepare 
training and test sets to build and validate four global QSAR models. Corresponding data on 
luciferase interference, a potential artefact in the applied AhR activation assay, was taken into 
account to remove potentially false positive experimental results from the AhR activation dataset at 
the data curation step. Due to the high ratio of 204,513 AhR activation inactives to 925 actives in the 
curated dataset, we used this dataset to explore how a stepwise rational selection of inactives to 
expand training set size would affect the coverage and predictive performances of the QSAR models.  
                                                     
22 http://www.sciencedirect.com/science/journal/aip/24682020  
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2. Material and Methods 
2.1 Experimental datasets 
A dataset consisting of structure information and qHTS in vitro data for human AhR activation and 
luciferase interference was used when constructing training and test sets. All data were downloaded 
from PubChem. In total, 324,858 chemicals had been tested in a primary singlicate screening for AhR 
activation, i.e. AID 2796, and given a PubChem activity score of 0-100 as described elsewhere [16]. 
Of the 7,990 substances originally tested active in AID 2796, 2,281 had been retested in triplicate for 
AhR activation, i.e. AID 2845 [17], and of these, 1,982 were confirmed AhR activators, i.e. PubChem 
activity score of 10-100 [17]. The AhR activation qHTS in vitro assay applied in AID 2796 and AID 
2845 is a luminescence-based assay using HepG2 cells stably transfected with AhR-dependent 
pGudLuc6.1-DRE plasmids [17]. Substances that activate AhR result in expression of the luciferase 
reporter gene, and the level of luciferase activity is an indirect measure of AhR activation [17]. Some 
substances can stabilize luciferase and increase its half-life resulting in its accumulation and a 
measured increase in luminescence signal [18], and such substances may be incorrectly interpreted 
as AhR activators in the applied AhR activation qHTS assay. We used experimental PubChem data 
from the luciferase inhibition/activation qHTS assay AID 5888342 [19] as a counterscreen to identify 
any such substances among the 1,982 confirmed AhR activators from AID 2845. We classified 
substances in AID 2845 with a PubChem activity score from 10 to 100 and a PubChem activity score 
of 0 in AID 588342 as active for AhR activation. Substances with a PubChem score of 0 in AID 2796 
were classified as inactive for AhR activation. The remaining substances were classified as 
inconclusive for AhR activiation. 
2.2 Structure preparation and dataset splitting 
The QSAR software applied in this study, Leadscope® Predictive Data Miner (LPDM), a component of 
Leadscope® Enterprise Server version 3.2.4, can handle organic chemical substances with a known 
and unambiguous 2D structure [20]. Briefly, we prepared calculation structures by first breaking 
ionic bonds and neutralizing the structures. Then we removed substances containing two or more 
organic components and structures with less than two carbon atoms from the dataset. Also, 
structures containing atoms not on the following list were removed: H, Li, B, C, N, O, F, Na, Mg, Si, P, 
S, Cl, K, Ca, Br, and I. Finally, structures with charges in their calculation structures were removed 
from the dataset. Canonized SMILES were generated for the remaining calculation structures in the 
dataset so that they were described following the same algorithm (Figure 1, pink box) and these 
constituted the QSAR-ready structures that were used for further processing. 
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In the next step, identical QSAR-ready structures in the dataset were identified and their 
experimental results, as classified above, were compared. For identical structures with concordant 
activities, only one of the structures was kept in the dataset, while if a group of identical structures 
had discrepant activities then the whole group was removed from the dataset (Figure 1, pink box). 
After structure preparation and duplicates removal, the dataset was split as follows. Among the 925 
AhR activation actives in the dataset, 10% were randomly selected to be used in a test set. This 
resulted in 93 test set actives and 832 training set actives. From the 204,513 QSAR-ready inactives in 
the dataset, we randomly selected 50.000 of the structures (to be called the ‘50K set’ below) to be 
used in the model development steps as explained below, while the remaining 154,513 structures 
were included in the test set (Figure 1, pink box).  
 
Figure 1. An overview of the workflow. Pink box: the steps of data curation and preparation of a test set and a 
dataset for training set construction. Light blue box: the steps of training set inactives selections and model 
building. Dark blue box: predicting the test set for external validation and the REACH-PRS set in the four 
models. Green box: inter-model comparisons of the predictive performances from the external validations and 
the coverages of the REACH-PRS set.  
2.3 Applicability domain definition 
The definition of the AD applied in this study consists of two components: 1) the definition of a 
structural domain in LPDM, and 2) a DTU Food in-house class probability refinement on the output 
from LPDM:  
1) For a query compound to be within LPDM’s structural domain it is required that: it has at least 
30% Tanimoto similarity with a training set compound, all molecular descriptors used in the model 
can be calculated and it contains at least one structural feature used in the model [21]. The 30% 
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Tanimoto similarity was a default cut-off in the LPDM software. For a test compound outside this 
structural domain no prediction call, i.e. active/inactive, is generated by LPDM. For test compounds 
within the LPDM structural domain, a positive prediction probability, p, between 0 and 1, is given 
together with the prediction call; actives having a p ≥ 0.5 and inactives having a p < 0.5 [21].  
2) The DTU Food class probability refinement served to exclude the likely less reliable predictions, 
i.e. those with a positive prediction probability close to the cutoff p = 0.5. For predictions to be 
within the AD we required a p ≥ 0.7 for active prediction calls (POS_IN) and a p ≤ 0.3 for inactive 
prediction calls (NEG_IN). Predictions within the LPDM structural domain but with an associated 
positive prediction probability in the interval 0.3 < p < 0.5 (NEG_OUT) and 0.5 ≤ p < 0.7 (POS_OUT) 
are defined as out of AD. 
2.4 QSAR Modeling 
In this study, we used the commercial software LPDM to build QSAR models. Briefly, upon dataset 
import LPDM calculates nine molecular descriptors (AlogP, Hydrogen Bond Acceptors and Donors, 
Lipinski Score, Molecular Weight, Parent Atom Number, Parent Molecular Weight, Polar Surface 
Area, Rotatable Bonds) and performs a systematic sub-structural analysis using a template library of 
more than 27,000 pre-defined structural keys for each chemical structure in the dataset [22]. For 
QSAR modeling in LPDM, the molecular descriptors and structural features are included in a default 
preliminary descriptor set. From the preliminary descriptor set, an automatic descriptor pre-
selection procedure in LPDM selects the top 30% descriptors according to Yates X2-test for a binary 
response variable. For training sets with a binary response variable, a predictive model is built using 
the pre-selected descriptors in a partial logistic regression (PLR) with further selection of descriptors 
in an iterative procedure, and selection of the optimum number of PLR factors based on minimizing 
the predictive residual sum of squares. LPDM has the option of building composite models, a type of 
ensemble models, for training sets with an imbalanced distribution of actives and inactives [23]. 
With this option a number of sub-models are created by specifying the desired ratio of actives to 
inactives per sub-model training set. The positive prediction probability (see 2.3) for a query 
chemical from a composite model is defined as the average of the positive prediction probabilities 
from all sub-models having the test chemical in their structural domain [21]. 
To first find the maximal modeling capacity in LPDM of the present dataset, we did a series of 
modeling experiments using training sets with different ratios of the 832 actives and randomly 
selected inactives from the 50K set. The training set with a ratio of 4:1, i.e. consisting 3,328 inactives 
randomly selected and the 832 actives, was the largest imbalanced training set that LPDM could 
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efficiently model. This 4:1 training set was later used for building a reference model for evaluating 
the effect of the rational selection steps described below. 
After determining the maximum training set inactive:active ratio we started to construct a 4:1 
training set using a two-step rational selection procedure. We first created a training set with an 
inactive:active ratio of 2:1 that consisted of the 832 actives and 1,664 (i.e., twice the 832 actives) 
inactives selected randomly from the 50K set of inactives (Figure 1, light blue box). The 2:1 training 
set was modeled in LPDM using three QSAR modeling approaches, which all underwent a 10 times 
20%-out LPDM cross-validation: 
1) A single model, i.e. a non-composite model using the full training set 
2) A composite model, with sub-models from balanced sub training sets and equal weight 
3) A composite ‘cocktail’ model, combining the single model from 1) with the sub-models of 
the composite model from 2) 
Since the main purpose in this study was to compare the predictive performances and coverages 
between models built from training sets constructed using two different selection approaches, we 
decided that all models should be built using the same modeling approach. Based on the LPDM 
cross-validation results the best performing modeling approach was selected and the selected model 
was closed and named QSAR2:1. Then the 50K set minus the inactive structures in the 2:1 training 
set, i.e. 48,336 inactive structures, were predicted in QSAR2:1 (Figure 1, light blue box). From these 
predictions, 832 new inactives were selected and added to the 2:1 training to constitute a 3:1 
training set as follows. The rational selection was done by selecting one fourth, corresponding to 208 
structures, randomly from each of the four prediction outcome areas (defined in 2.3):  
1. out of LPDM structural domain 
2. POS_OUT 
3. NEG_OUT 
4. POS_IN, i.e. here false positive (FP) predictions  
The addition of structures from 1. through 3. mainly served to increase chemical space of the 
subsequent training set with the purpose of increasing the AD and model coverage. The structures 
with POS_IN predictions, i.e. 4., were added with the purpose to improve the ability of the model 
algorithm to avoid deriving false activity features and thereby reduce its tendency to make FP 
predictions. A similar but smaller effect on performance was expected from addition of the 
POS_OUT (2.) and NEG_OUT (3.) selected structures.  
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The 3:1 training set was used for building a QSAR model using the selected modeling approach, and 
the model was closed and named QSAR3:1. The 50K minus the 3:1 training set inactive structures, 
i.e. 47,504 inactive structures, were then predicted in QSAR3:1 and from the predictions, 832 
inactives were selected as described above and added to the 3:1 training set to constitute a 4:1 
training set (Figure 1, light blue box). Again, the 4:1 training set was used for building a QSAR model 
using the selected modeling approach and the model was closed and named QSAR4:1. To have a 
reference model to evaluate the effect of the rational selection steps against, the 4:1 training set 
with the inactives randomly selected from the 50K set were used for building a model using the 
selected modeling approach. This model was closed and named QSAR4:1-R. 
2.5 Validation of the QSAR models 
All four selected and closed models, QSAR2:1, QSAR3:1, QSAR4:1 and QSAR4:1-R, had during their 
development undergone a 10 times 20%-out cross-validation procedure in LPDM. The LPDM cross-
validation applies the LPDM structural domain only and is not a true cross-validation as the 
algorithm transfers knowledge from the full training set model to the smaller cross-validation 
models. Therefore, the LPDM cross-validation results were only used in a relative manner to guide 
the selection of the modeling approach (see 2.4) and not to estimate absolute predictive 
performance. To assess the models predictive performances, the four closed models were subjected 
to an external validation using the test set of 93 AhR actives and 154,513 inactives (Figure 1, dark 
blue box). Sensitivity, specificity and balanced accuracy were calculated for the test set predictions 
within the defined AD. Sensitivity is the percentage of experimental actives correctly predicted, 
specificity is the percentage of the experimental inactives correctly predicted, and balanced accuracy 
is the average of the sensitivity and specificity. The coverage of the test set, i.e. the percentage of 
how many of the predicted test set structures that had predictions within the defined AD, was also 
calculated for all four QSAR models. 
2.6 Screening of 72,524 REACH substances for AhR activation 
An EU collection of 72,524 substances from the REACH pre-registered substances (PRS) list extracted 
from the online Danish (Q)SAR Database structure set [24,25] was screened through the four AhR 
activation QSAR models (Figure 1, dark blue box). The 72,524 QSAR-ready structures were originally 
curated from deliverable 3.4 of the OpenTox EU project [26] and had previously been processed 
through the structure preparation steps described in 2.2. The proportion of the 72,524 QSAR-ready 
REACH-PRS structures predicted within the defined AD of each of the four QSAR models, 
respectively, as well as the activity distributions of the predictions were calculated.  
 Part III  
109 
 
2.7 Comparison of model coverages and predictive performances  
To uncover the effect of the two-step rational selection of inactives for the QSAR4:1 training set, an 
analysis of the coverages of the REACH-PRS set and the test set in the four models was performed. 
The results from the external validation of the four models using the test set were also compared to 
assess the effect of the stepwise rational selection procedure with regard to predictive performance. 
The analyses and comparisons were focusing on QSAR4:1 versus QSAR4:1-R as well as between the 
intermediate models QSAR2:1 and QSAR3:1 versus QSAR4:1 (Figure 1, green box). 
3. Results and Discussion 
Here we describe a pilot study to explore how a large and highly inactive-imbalanced dataset could 
be used for developing global QSAR models with optimized coverages and predictive performances. 
3.1 The datasets 
According to our classification of AhR actives and inactives described in 2.1 the initial dataset 
contained 932 actives and 209,118 inactives. During the structure preparation and duplicates 
handling in 2.2, a total of 4,612 structures were removed from the dataset, 2,909 due to the 
structural QSAR criteria and 1,703 due to structural duplicates, none of which due to conflicting 
experimental results (Figure 1, pink box). The number of QSAR-ready structures and the distribution 
of active and inactive experimental results in the full curated dataset, the test set, the 50K set for 
training set selection of inactives as well as the four training sets are summarized in Table 1.  
Table 1. Overview of the datasets and their distributions of active and inactive experimental results. 
Dataset overview Actives Inactives Total 
Full dataset 925 204,513 205,438 
Test set 93 154,513 154,606 
50K set 0 50,000 50,000 
2:1 training set  832 1,664 2,496 
3:1 training set  832 2,496 3,328 
4:1 training set  832 3,328 4,160 
4:1-R training set  832 3,328 4,160 
3.2 Selection of model building approach 
The 2:1 training set was used for building three QSAR models applying three different modeling 
approaches in LPDM. Their LPDM cross-validation results are given in Table 2. These results were 
used for selecting the modeling approach and not for estimating model predictive performance. As 
can be seen from Table 2, all three modeling approaches showed similar balanced accuracies from 
81.3% to 83.7% in the 10 times 20%-out LPDM cross-validation. The lower LPDM sensitivity of the 
single model was expected due to the imbalance of the training set. The 2:1 training set composite 
‘cocktail’ model 3) was the modeling approach that produced the highest number of both true 
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positive (TP) and true negative (TN) predictions and it resulted in more moderate numbers of FP and 
false negative (FN) predictions compared to the two other approaches. Based on these numbers, 
and on the fact that the composite modeling approach in LPDM is designed to handle imbalanced 
training sets, we selected the composite modeling approach 3) for future modeling of the remaining 
training sets, 3:1, 4:1 and 4:1-R. 
Table 2. The results from the 10 times 20%-out LPDM cross-validations of the three modeling approaches 
applied on the 2:1 training set. 
2:1 training set  Predictions in LPDM structural domain Statistical parameters 
Modeling 
approach TP TN FP FN 
Sensitivity, 
% 
Specificity, 
% 
Balanced 
accuracy, % 
1) Single 587 1423 154 224 72.4 90.2 81.3 
2) Composite 666 1266 262 122 84.5 82.9 83.7 
3) ‘Cocktail’ 670 1427 224 162 80.5 86.4 83.5 
TP = true positive, TN = true negative, FP = false positive, FN = false negative 
3.3 Predictive performance assessment by external validation 
After building the four models as described in 2.4, they were all subjected to external validation with 
the test set. In Table 3, the external validation results from the four QSAR models are given. An 
overall increase was seen when comparing the predictive performances from the external 
validations of QSAR2:1, QSAR3:1 and QSAR4:1. The stepwise rational selection with addition of 
inactives to the 2:1 and 3:1 training sets gave a total increase in specificity of 7%, i.e. from 90.2% in 
QSAR2:1 to 97.2% in QSAR4:1. The sensitivity was more or less unaffected and ranged from 83.6% to 
85.7% without a trend between the models, and these small differences in the sensitivities are likely 
mainly due to noise.  
Table 3. The results from the external validation of the four models including model coverage of the test set. 
External validation QSAR2:1 QSAR3:1 QSAR4:1 QSAR4:1-R 
Statistical 
parameters, % 
Sensitivity (TP/(TP+FN)) 85.7 83.6 85.1 89.8 
Specificity (TN/(TN+FP)) 90.2 95.3 97.2 91.6 
Balanced accuracy 88.0 89.5 91.2 90.7 
POS_IN 
TP 60 46 40 53 
FP 11,605 5,652 3,320 10,017 
NEG_IN 
TN 107,377 114,165 115,045 109,320 
FN 10 9 7 6 
Coverage 
 
Of 93 actives  
(%) 
70 
(75.3) 
55 
(59.1) 
47 
(50.5) 
59 
(63.4) 
Of 154,513 inactives 
(%) 
118,982 
(77.0) 
119,817 
(77.5) 
118,365 
(76.6) 
119,337 
(77.2) 
In total  
(%) 
119,052 
(77.0) 
199,872 
(77.5) 
118,412 
(76.6) 
119,396  
(77.2) 
The test set consisted of 93 actives and 154,513 inactives. TP = true positive, TN = true negative, FP = false positive, FN = false negative 
A comparison of the external validation statistical parameters from QSAR4:1 and QSAR4:1-R showed 
that the QSAR4:1 model had a higher specificity, i.e. 97.2% versus 91.6%, but a lower sensitivity, i.e. 
85.1% versus 89.8%, than the QSAR4:1-R (Table 3). The positive effect on the specificity was an 
 Part III  
111 
 
expected result from the procedure of rational addition of inactives selected among the POS_IN and 
POS_OUT predictions produced by the preceding models. Inclusion of these structures with false 
positive predictions in the training set can help the subsequent model train on a more 
representative chemical space and thereby make more correct predictions. 
3.3 Model coverages  
Another focus of this study was to explore how the selection of inactives for the training sets would 
affect future model coverages. In Table 3, the coverages of the test set in the four models are given 
and as can be seen all models showed test set coverages of 76.6% to 77.5%. Thus, no effect on 
overall test set coverage was seen from the two-step rational versus the random selection. Although 
the inter-model total coverages are similar, there are clear differences in the absolute number of TP, 
TN, FP and FNs, respectively, produced from the four models (see Table 3). The QSAR4:1 and 
QSAR4:1-R coverages of the small number of 93 test set actives were 50.5% (47/93) and 63.4% 
(59/93), respectively. Due to the low active-to-inactive ratio in the test set, i.e. 93 actives to 154,513 
inactives, the differences in the coverages of actives between the models are blurred in the total 
coverage measures (Table 3). 
Besides screening the test set structures in the four models, the REACH-RS inventory of 72,524 man-
made chemicals was also predicted by the models. The prediction and coverage results from the 
REACH-PRS screening can be found in Table 4. In Figure 2, the coverages of the REACH-PRS are 
shown. 
Table 4. Overview of the screening results from the REACH-PRS set  
REACH-PRS screening QSAR2:1 QSAR3:1 QSAR4:1 QSAR4:1-R 
Coverage  
(%) 
31,611  
(43.6) 
40,418  
(55.7) 
46,261  
(63.8) 
39,698  
(54.7) 
POS_IN 2,744 1,483 1,269 2,148 
NEG_IN 28,867 38,935 44,992 37,550 
When comparing the coverages of the REACH-PRS set in the two intermediate models QSAR2:1 and 
QSAR3:1 to QSAR4:1, a total increase in coverage of 20% can be observed (Figure 2 and Table 4). 
This increase was an expected effect of the gradual increase in training set size, and was especially 
an effect of the large increase in NEG_IN predictions relative to the fall in POS_IN predictions (Table 
4). Despite the same number of actives and inactives in the QSAR4:1 and QSAR4:1-R training sets, 
the coverage of REACH-PRS was almost 10% larger in QSAR4:1, which is most likely an effect of the 
rational selection steps. Also here, QSAR4:1 produced more NEG_IN predictions, i.e. 44,992 versus 
37,550, with a smaller absolute decrease in its number of POS_IN outputs, i.e. 1,269 versus 2,148, 
relative to QSAR4:1-R. 
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Figure 2. Coverage of the REACH-PRS set in the four QSAR models. 
The more NEG_IN predictions produced by QSAR4:1 are likely a result of an increased structural 
diversity of inactives in the rational selected training set. This increase in structural diversity and the 
AD is mainly driven by the addition of structures with predictions out of LPDM structural domain (1.) 
in the preceding model as well as adding structures with NEG_OUT predictions that may have helped 
the subsequent model make more clear predictions, i.e. NEG_IN, for these types of structures. The 
addition of 50K inactive structures with false POS_IN and POS_OUT predictions in the intermediate 
models has likely helped the QSAR4:1 model reduce its rate of FP predictions, and is part of the 
reason for the smaller number of POS_IN REACH-PRS predictions generated from QSAR4:1. 
However, since the rational addition of structures was only aimed at increasing the number and 
diversity of inactive structures in the training set without a corresponding increase in training set 
actives, the addition of structures in the POS_IN and POS_OUT prediction areas has also resulted in a 
sacrifice of the number of TP predictions produced by QSAR4:1. This can also be seen in the results 
from the test set, where QSAR4:1 resulted in 40 TP predictions out of the 93 test set actives as 
opposed to the 53 TP predictions from QSAR4:1-R (Table 3).  
Overall, these results indicate that the rational selection procedure of training set inactives for 
QSAR4:1 has produced a model with enlarged coverage of the large REACH-PRS prediction set (from 
54.7% to 63.8%). The same effect was for unknown reasons not seen for the test set, instead a 
reduction in the coverage of the 93 actives (from 63% to 51%) was observed. The QSAR4:1 model 
according to the external validations produced the highest number of TNs but also the fewest TPs.  
Depending on the purpose of the QSAR screening, the four models may serve different aims. If the 
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QSAR screening is for example aiming at finding as many TPs as possible at the expense of a higher 
number of FPs, then the external validation indicates that QSAR2:1 is the best model.  
4. Conclusions 
Overall, the external validations showed that all four models had high predictive performances with 
balanced accuracies of 88.0% to 91.2%. From this pilot study, we can conclude that the stepwise 
rational selection of training set inactive structures from a very large and imbalanced datasets 
improved model specificity, i.e. ability to correctly predict the inactives, from 91.6% to 97.2% 
compared to random selection. The coverage improvement effect of the rational selection 
depended on the constitution of the prediction set, and here we saw an approximately 10% 
coverage increase of the REACH-PRS set but no improvement in test set coverage.  
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3.4 The Collaborative Estrogen Receptor Activity Prediction Project   
3.4.1 Introduction  
The Collaborative Estrogen Receptor Activity Prediction Project, abbreviated CERAPP, was initiated 
in 2013 by the U.S. EPA NCCT under the Endocrine Disruptor Screening Program (EDSP) laid out in 
1998 [1–3]. In EDSP, a two-tiered approach is applied to screen a universe of around 10,000 
chemicals for their potential to be endocrine disruptors. The Tier 1 screening consists of a battery of 
11 endocrine-related in vitro and in vivo assays [4] that would cost  around 1,000,000 USD/chemical, 
use a minimum of 520 animals/chemical and have a throughput of approximately 50 chemicals/year 
[3,5]. This challenge initiated the idea of a pre-tier 1 filter [6]. The aim of CERAPP was to use 
structure-based computer models to predict the full EDSP universe for estrogen receptor (ER) 
activity to aid in prioritizing EDSP chemicals for further Tier 1 testing. Due to the ease and low cost of 
running such models, the chemical universe for ER activity prediction was expanded to cover most of 
the man-made chemicals with potential human exposure in the United States [3,7]. The U.S. EPA 
NCCT contacted relevant research groups, including the QSAR team at DTU Food, to request them 
for participation in CERAPP, which in January 2016 resulted in a scientific publication [7], describing 
the methods and main results from the project.  
Briefly, the CERAPP project is focused on the ER signaling pathway activation, an important 
mechanism of another area of the endocrine system and not directly considered a mechanism of 
thyroid hormone disruption. However, some common links between the ER signaling pathway and 
the thyroid system do exist, for example are some of the enzymes regulated by e.g. AhR and PXR 
involved in the synthesis and/or metabolism of both estrogens and THs [8,9]. Furthermore, cross-
talk between ER and e.g. AhR may indirectly affect ER signaling and/or TH catabolism [10,11]. Also, 
estrogens have an effect on TH economy and function [12] and vice versa [13]. Thus, the thyroid and 
estrogen systems do interact [14] and together affect e.g. brain development and regulation of 
behavior [15]. 
3.4.2 My Contributions to CERAPP 
My contributions to the CERAPP project consisted of building a binary global QSAR model in LDPM 
using the U.S. EPA NCCT provided ToxCast training set of 80 actives and 1,342 inactives for ER 
agonism and documenting the developed QSAR model in the QMRF format (Appendix). The QSAR 
team at DTU Food then predicted the U.S. EPA NCCT provided prediction set in the ER agonist QSAR 
model as well as in two previously built QSAR models for human ERα binding [16]. The predictions 
inside the defined AD (see AD definition in the QMRF, Appendix) of the ER agonism QSAR model as 
well as the QMRF were sent to U.S. EPA NCCT, who evaluated the model based on the predicted 
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evaluation set as described in the paper. Besides the work made for CERAPP, the model underwent a 
robust cross-validation (Appendix) and was applied for screening the REACH-PRS inventory of 72,524 
chemical structures pre-registered under REACH [17]. The result from the cross-validation revealed a 
highly predictive model with a specificity of 94.4% and a sensitivity of 80.6%. Of the screened 
REACH-PRS set, 53,433 (73.7%) structures had predictions within the defined AD, and of these 4,918 
were predicted ER agonists. 
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3.4.3 Published paper 
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The supplemental material is available online at http:// dx.doi.org/10.1289/ehp.1510267.  
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3.4.4 My Further Remarks to CERAPP 
The approach applied in CERAPP has its limitations both with regard to the biological endpoint and 
the methods for evaluating the individual models and constructing the consensus model. First, the 
U.S. EPA NCCT provided ToxCast training sets was derived from a network model that integrates 
results from 18 in vitro assays [18]. These 18 assays covers the steps of the classical ER signaling 
pathway starting from ligand binding to the ER ligand binding domain, dimerization, co-factor 
recruitment and DNA binding as well as protein production and ER-induced proliferation for the ER 
agonists [18]. EDCs can affect estrogen signaling through other estrogen signaling pathways and 
indirect mechanisms [19–22]. Therefore the negative predictions from CERAPP should not be used 
for acquitting chemicals as having estrogen modulating potential.  
The evaluation method used in CERAPP does not constitute a proper external validation of the 
models (section 2.3.1) as the evaluation set contains both U.S. EPA NCCT ToxCast training set 
structures and structures applied in other training sets. Thus, depending on the degree to which the 
evaluation set structures were also included in the training set of the models, the performance 
results are likely to be affected. The models with a high overlap of training and evaluation set 
structures have most likely also performed better in the evaluation. As described in the paper, the 
results from the evaluations were included in the assignment of the two model scores. These scores 
were subsequently used when constructing the consensus model. The potential bias introduced to 
these scores evaluations could hereby have influenced the constructed consensus model and its 
predictions. However, the reason for making the consensus model was to overcome the limitations 
of the single models in terms of their coverage and applied algorithms, and this was not 
compromised by the evaluation procedure. Also, the main goal of CERAPP was to use the consensus 
model predictions for prioritizing chemicals for further testing in EDSP and not to develop a high 
performance consensus model [3]. Performing true robust external validations of the many models 
included in CERAPP would have been both impractical and very time-consuming. 
3.4.5 Conclusions 
To conclude, the approach and predictions from CERAPP serve as useful prioritization tools for 
further testing of e.g. the EDSP universe, but the negative predictions cannot be used for classifying 
chemicals as non-EDCs just as the model evaluation results should not be interpreted as external 
validations. To conclude on the additional work made, the ER agonist model developed for CERAPP 
showed high predictive performance in an in-house robust cross-validation with balanced accuracy 
of 87.5%. In the screening of the REACH-PRS set the model could predict 73.7% of the substances 
and of these 4,198 chemicals were predicted as potential ER agonists.  
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4.1 Overview 
To recapitulate on the four projects in this thesis, a brief summary of each project and its main 
results is given below. The predictive performances of the QSAR models from each project as well as 
their coverages of the REACH-PRS set of 72,524 structure entries are summarized in Table 1. 
Table 1. Overview of the predictive performances and coverage of the REACH-PRS set for the QSAR models 
developed in this thesis. 
Overview Cross-validation External validation REACH-PRS screening 
Project QSAR models Sens Spec BA Sens Spec BA 
Coverage 
(%) POS_IN NEG_IN 
TPO 
QSAR1 72.1 89.0 80.9 79.7 90.8 85.3 38,661 (53.3) 7,128 31,533 
QSAR2 75.6 89.8 82.7 - - - 45,540 (62.8) 8,790 36,750 
PXR  
and 
CYP3A4 
hPXR-LBD 68.7 84.5 76.6 85.0 87.8 86.4 43,551 (60.1) 11,490 32,061 
hPXR 72.5 80.4 76.4 80.0 85.2 82.6 38,114 (52.5) 6,167 31,947 
rPXR 58.9 92.0 75.4 91.3 94.1 92.7 52,144 (71.9) 3,141 49,003 
CYP3A4 71.6 80.7 76.1 76.9 85.5 81.2 42,861 (59.1) 5,874 36,987 
AhR 
QSAR4:1 - - - 85.1 97.2 91.2 46,261 (63.8) 1,269 44,992 
QSAR4:1-R - - - 89.8 91.6 90.7 39,698 (54.7) 2,148 37,550 
CERAPP ER agonism 80.6 94.4 87.5 - - - 
53,433 
(73.7) 4,198 49,235 
Sens = sensitivity, Spec = specificity, BA = balanced accuracy, AD = applicability domain, POS_IN = positive prediction in the defined AD, 
NEG_IN = negative predictions in the defined AD 
Chapter 3.1: QSAR Models for TPO Inhibition In Vitro 
The main aim of this project was to develop and apply global binary QSAR models for TPO inhibition, 
an important mechanism for thyroid disruption and an MIE in a thyroid-related AOP for DNT. 
Main methods and results: Two QSAR models were built and validated: 
• QSAR1: the training set consisted of 877 ToxCast phase I and II chemicals. The QSAR model 
underwent robust cross-validation as well as external validation with a large test set of 646 E1K 
ToxCast chemicals. 
• QSAR2: the test set and training set for QSAR1 were merged to constitute a training set of 1,519 
ToxCast chemicals, and a new larger QSAR model was built and cross-validated. 
The cross-validation procedure was conservative compared to the external validation of QSAR1 
(Table 1). Overall, both QSAR1 and QSAR2 showed high predictive performances according to their 
respective validations, i.e. balanced accuracies from 80.6% to 85.3% (Table 1). The top ten structural 
features in QSAR2 associated with TPO inhibition and non-inhibition, respectively, were identified, 
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and among structural features associated with TPO inhibition were versions of phenols, aniline and 
anisole. The EU REACH-PRS inventory and a US-EPA inventory of 32,197 unique structures were 
screened through QSAR1 and QSAR2. QSAR2 had approximately 10% larger coverages of REACH-PRS 
and US-EPA, which was an expected effect of expanding the training set (Table 1). The two isomers 
of BHA, both included in the inventories and used as e.g. food antioxidants, were used in a case 
study to exemplify one use of QSAR predictions, i.e. how QSAR predictions can aid in elucidating a 
chemical’s mode-of-action(s) in AOs and support results from in vivo studies. The project has been 
described in a manuscript ready for submission. 
Chapter 3.2: QSAR Models for PXR Interaction and CYP3A4 Induction In Vitro 
The main aim of this project was to develop global binary QSAR models for PXR binding and 
activation as well as CYP3A4 induction. PXR regulates the expression of metabolizing enzymes, 
including CYP3A4, and some of these enzymes are involved in thyroid and estrogen hormone 
catabolism. PXR also regulates expression of proteins important for thyroid hormone membrane 
transport. Activation of PXR by xenobiotics can therefore induce thyroid disruption and is included as 
an MIE in an AOP for thyroid-related DNT. 
Main methods and results: Four global binary QSAR models for hPXR-LBD binding, hPXR activation, 
rPXR activation and CYP3A4 induction, respectively, were built and underwent robust cross- and 
external validations. They were all robust and predictive with balanced accuracies of 75.4% to 76.6% 
in cross-validations and 82.6% to 92.7% in external validations (Table 1). The models were 
subsequently used for screening the REACH-PRS inventory, and could produce reliable predictions 
for 52.5% (hPXR) to 71.9% (rPXR) of the structures (Table 1). Concordance rates between relevant 
model endpoints were calculated on both the REACH-PRS predictions and the experimental data. 
From this, we saw a high overlap of 81% between predicted hPXR activators that were also predicted 
hPXR-LBD binders as well as between predicted hPXR activators being CYP3A4 inducers (88.4%) and 
vice versa (97.5%). We did not see any positive correlations between hPXR and rPXR activators, and 
these results emphasize the need to be careful when extrapolating rat toxicity data to humans. The 
project results have been published in [1] as an open access paper. 
Chapter 3.3: QSAR Models for AhR Activation In Vitro 
The main aim of this project was to use a large and highly imbalanced PubChem dataset for AhR 
activation to explore how a rational two-step selection of inactives for training set expansion would 
affect QSAR coverage and predictive performance. AhR, like PXR, regulates the expression of 
enzymes involved in estrogen and thyroid hormone catabolism, and AhR interaction is an MIE in a 
thyroid-related AOP for DNT. 
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Main methods and results: The large and imbalanced curated dataset was randomly split into a test 
set (93 actives and 154,513 inactives) and a dataset (832 actives and 50,000 inactives) for training 
set construction. The 832 training set actives were used in all training sets and different proportions 
of inactives were selected from the 50K set of inactives using two different approaches: random vs 
two-step rational selection. Two final QSAR models with an inactive to active ratio of 4:1 were made: 
• QSAR4:1-R: consisted of the 832 actives and 3,328 inactives selected randomly from the 50K 
inactives. 
• QSAR4:1: consisted of the 832 actives and 3,328 inactives selected in one random and two 
rational selection steps using predictions of the remaining 50K set structures in two 
intermediate models. This rational selection aimed at identifying and adding structures that 
could help expand the chemical space covered by the training set and improve the model’s 
ability to correctly discriminate between actives and inactives. 
The models were externally validated with the test set, and QSAR4:1 produced a higher number of 
true negative predictions and a smaller number of both false and true positive predictions compared 
to QSAR4:1-R. Thus, QSAR4:1 had a higher specificity (97.2% versus 91.6%) than QSAR4:1-R but a 
lower sensitivity (85.1% versus 89.8%) (Table 1). These results indicate that the two-step rational 
selection of inactives for QSAR4:1 has resulted in a model with an optimized ability to produce more 
reliable predictions of inactives at the expense of both correct and wrong active predictions. Then 
the models were used for screening of the REACH-PRS inventory. QSAR4:1 had around 9% larger 
coverage of the REACH-PRS set than QSAR4:1-R, i.e. 63.8% versus 54.7% (Table 1). For unknown 
reasons the same effect in coverages of the test set was not observed. 
The projects in chapter 3.1, 3.2 and 3.3 cover relevant thyroid-related mechanisms and were all part 
of a project partly supported by a grant from the Danish 3R Center23. 
Chapter 3.4: The Collaborative Estrogen Receptor Activity Prediction Project  
This project was part of the large international collaboration, CERAPP, organized by the U.S. EPA 
NCCT on building QSARs for the classical ER signaling pathway and using them to make consensus 
predictions for a CERAPP prediction set of around 32,500 U.S. EPA curated environmental chemicals. 
The output from CERAPP has been published in [2].  Activation of ER is an important mechanism in 
the endocrine system and is one of the best-studied effects of ECDs. It is indirectly related to thyroid 
hormone disruption due to e.g. ER cross-talk with thyroid-related mechanisms such as the AhR.  
                                                     
23 http://en.3rcenter.dk/research/projects/projects-2016/development-of-mechanism-based-computer-
models-for-hazard-assessment-of-thyroid-hormone-disruption/ 
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Main methods and results: My contributions to CERAPP consisted of the development of a binary 
global QSAR model for ER agonism using a U.S. EPA provided training set. The model was rigorously 
cross-validated and showed high predictive performance in the cross-validation with a balanced 
accuracy of 87.5% (Table 1). The model and cross-validation were described in the QMRF format 
(Appendix), which was sent to U.S. EPA together with predictions of the CERAPP prediction set 
generated by the DTU Food QSAR team. U.S. EPA NCCT scientists performed evaluations of the 
individual models using an evaluation set included in the prediction set and used these results when 
they combined the corresponding model predictions provided by all the collaborators to reach 
consensus predictions on the CERAPP prediction set. The U.S. EPA evaluation set was not screened 
for training set overlap and could therefore not be used for external validation but only to weigh the 
single model predictions in the CERAPP consensus prediction. Besides the work made for CERAPP, I 
also applied the ER agonism QSAR model to screen the REACH-PRS set, and the model could make 
reliable predictions for 53,433 (73.7%) of the structures, and of these 4,198 were predicted ER 
agonists (Table 1). 
Each project has been discussed in the respective project chapters. The next chapter contains a 
more general discussion of all four projects in relation to the background chapters followed by some 
concluding remarks and a short reflection on future research perspectives. 
4.2 Discussion 
The thyroid-relevant mechanisms covered in the projects of the PhD thesis include inhibition of TPO 
and interaction with the two NRs, PXR and AhR. The selection of these mechanisms for global binary 
QSAR development was primarily based on the availability of large and structurally diverse datasets 
with high quality experimental results as well as their relevance in established thyroid-related AOPs 
for DNT. Also, the selected datasets had to be useful for QSAR modeling, i.e. they should have 
contained sufficient data for both activity classes. The inclusion of the CERAPP project (3.4) on ER 
agonism in the PhD project was mainly due to the invitation from the U.S. EPA NCCT to participate. 
Such participation was a great opportunity to strengthen the collaboration with the U.S. EPA NCCT 
for future QSAR development projects.  
4.2.1 Collection, Curation and Preparation of the Applied Datasets  
The training and validation sets in each project were collected from the same sources, respectively, 
and the experimental data had undergone the same testing protocol(s) and data analysis. 
Furthermore, in project 3.1 and 3.2 the models were developed in close collaboration with the data 
providers. In all the projects, the chemical structures underwent a structure curation procedure to 
remove structures inacceptable for QSAR processing. Most assays are associated with artefacts 
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related to the applied technology, e.g. luciferase or fluorescence interference, or protocol, e.g. 
cytotoxicity in cell cultures. Such artefacts can result in false positive or negative experimental 
results [3]. In the curation procedure of the datasets for 3.1, 3.3 and 3.4, different steps were taken 
to identify such potentially false experimental results. In 3.1 and 3.4, the U.S. EPA NCCT provided 
data had previously undergone different curation procedures using information from related assays 
to flag potentially false experimental results. For the AhR project, available PubChem data for 
luciferase interference were used as a counterscreen to flag potential false active results. Based on 
the flags for potential assay interference, we classified portions of the data entries as inconclusive 
for the given endpoint and excluded them from the subsequent model development. The structure 
curation and exclusion of inconclusive and potentially false experimental results have contributed to 
reducing the noise in the datasets.  
4.2.2 QSAR Development 
All the training and test sets were large and diverse enough to build global QSAR models and 
perform large external validations, respectively. Only QSAR models with binary, i.e. active versus 
inactive, response variables were made in this PhD project. This was done mainly due to the nature 
of the provided data. None of the models have had any outliers removed, and thus all available 
information to the extent possible was used in the model development. Wherever possible, the built 
QSAR models underwent both large external validation and rigorous five times two-fold cross-
validation to assess their predictive performances in the defined AD (Table 1). The experience from 
project 3.1 and 3.2 was that the applied cross-validation procedure underestimates the predictive 
performance compared to applied large external validations. Goodness-of fit tests have not been 
performed in the projects but have been made subsequently, and the results are available in Table 2.  
Table 2. Goodness-of-fit results of the QSAR models developed in this thesis. 
Goodness-of-fit Predictions in AD Statistical parameters 
Project Models TP FP TN FN Sensitivity Specificity 
Balanced 
accuracy 
TPO 
QSAR1 84 37 491 2 97.7 93.0 95.4 
QSAR2 147 53 846 13 91.3 94.1 92.7 
PXR and 
CYP3A4 
hPXR-LBD 111 117 892 6 94.9 88.4 91.7 
hPXR 133 120 757 11 92.4 86.3 89.4 
rPXR 81 65 1214 3 96.4 94.9 95.7 
CYP3A4 127 173 865 11 92.0 83.3 87.7 
AhR 
QSAR4:1 466 140 1965 37 92.6 93.3 93.0 
QSAR4:1-R 591 157 2475 42 93.4 94.0 93.7 
CERAPP ER agonism 64 52 1090 5 92.8 95.4 94.1 
TP = true positive, FP = false positive, TN = true negative, FN = false negative, AD = applicability domain 
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As expected, when comparing the balanced accuracies from the external and/or cross-validations 
(Table 1) with the corresponding goodness-of-fit balanced accuracies (Table 2), the goodness-of-fit 
results were better in all cases. Since all models showed good predictive performances with 
balanced accuracies over 75% in the cross-validations and 82% in the external validations (Table 1) 
this indicates that the models are able to generalize and have not been overfitted to their training 
sets.  
The good predictive performances of the models are likely a result of a combination of the following: 
• An overall high quality of the experimental datasets including the fact that all data in the 
respective datasets originated from the same source with experimental results from the same 
test protocol(s) 
• The structure and data curation steps to reduce noise in the datasets  
• The use of the composite model function in LPDM to increase performance of the smaller class 
in the imbalances training sets, i.e. sensitivity in these cases 
• The chemical descriptors and modeling method were adequate for the modeled endpoints 
• The application of a ‘strict’ AD to exclude the likely less reliable predictions from the statistical 
analyses 
4.2.3 Limitations of the Developed QSAR Models 
QSARs are, like other in silico, in vitro or in vivo studies, models that serve to estimate the true 
values, and false predictions are in general an unavoidable attribute of any (QSAR) model [4]. 
Validation of a model can provide measures of how good the model is at making correct estimates 
and information about the uncertainty in these estimates. As QSAR models are trained on 
experimental data from in vitro or in vivo models their predictive performance depend on the 
performance of the underlying experimental data. In theory a model can be more precise than the 
experimental results, but this is rare and difficult to prove. False predictions produced from the 
QSAR models can be a result of wrong information included in the model, e.g. due to unforeseen 
artefacts in the experimental data model or unknown chemical impurities causing the activity. They 
may also be due to the more rare cases where the QSAR, with help from its knowledge from training 
set structural analogs, have identified a wrong experimental result. Furthermore, a false QSAR 
prediction may reflect that the underlying similarity hypothesis is not bullet-proof, for example due 
to ‘activity cliffs’, i.e. areas in the chemical space where a small change in the chemical structure can 
have a dramatic effect on its activity [5–7]. If such information have not been included in the training 
of the model, then the model is unlikely to be able to identify such ‘activity cliffs’ when applied on 
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new structures. Finally, wrong predictions may be due to inappropriateness of the used modeling 
method or descriptors, as well as other reasons. 
The results from the robust cross- and external validation studies of the QSAR models described in 
this thesis gives useful information to the model user. The sensitivity and specificity measures 
quantify how good a model is at avoiding false negative and false positive predictions, respectively. 
For any test there is usually a trade-off between these two measures and whether a high specificity 
or a high sensitivity is preferred depends on the purpose of the model. If the purpose is to identify as 
many positives as possible and avoid false negative predictions then a model with a high sensitivity is 
preferable, however at the expense of risking a high rate of false positives. If the purpose is to be 
quite certain that a positive prediction is correct then a model with high specificity would be 
preferred. All models in this thesis had higher specificity than sensitivity in their validation(s) (Table 
1). This was mainly an effect of the higher ratio of inactives in the training sets but also partly driven 
by a deliberate choice in the modeling procedures  
4.2.4 Using the Developed QSAR Models  
The QSAR models developed in the PhD project can serve multiple uses and some have already been 
mentioned in the project chapters. Here a few examples are given and discussed in terms of their 
use limitations. 
For Screening and Prioritization 
Global QSAR models are useful tools for virtual screening of large chemical libraries. In the present 
PhD project, the developed global QSAR models were among other things applied to screen the large 
chemical inventory of 72,524 REACH-PRS substances. The models could predict between 38,114 
(52.5%) to 53,433 (73.7%) of the REACH-PRS structures in their respective ADs (Table 1). In this way 
the developed global QSAR models succeeded to substantially expand the experimental knowledge 
from the 1,000s of chemical structures they were trained on, and the QSAR-derived information on 
10,000s of chemicals can contribute to the identification and prioritization of potential EDCs, mainly 
TDCs, for further evaluations. As the models have high specificities we expect a fairly high rate of 
true positives among the positive predictions from the screenings but also a relatively high risk of 
not catching some positives due to many false negative predictions. Corresponding predictions from 
the developed models, as well as previously built QSARs, can also be used in combination to identify 
chemicals that are both inhibiting TH synthesis, i.e. are TPO inhibitors, and increasing TH catabolism, 
e.g. through PXR and/or AhR activation. Chemicals that affect both TH synthesis and catabolism are 
likely to have a more pronounced effect on TH levels and could be ranked as the highest priority 
chemicals. As all of the models have been trained to predict binary endpoints they cannot output 
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information of the chemicals potencies for the given mechanism. Such information could also have 
been useful in a ranking. 
In Research 
The QSAR models may aid in the development, optimization or repurposing of chemicals and drugs, 
for example drugs for treatment of thyroid-related diseases. They may also be used for generating 
new hypotheses on molecular mechanisms in AOs by searching for statistical correlations between 
chemicals predicted active for e.g. TPO inhibition and having data for an AO. Such data-driven 
associations will have to be investigated further in animal models to be confirmed or rejected. 
Finally, predictions from the present models can aid in the design of in vivo toxicity studies of 
chemicals by providing information on the chemical’s possible mode-of actions and potential AOs 
that could be investigated. 
In Regulatory Contexts 
Whether the developed models are applicable for regulatory use does not only depend on their 
ability to provide reliable predictions, but also of their regulatory relevance [8]. The developed 
models from the present project are of regulatory relevance and may serve multiple applications in 
regulatory contexts. They can for example provide information to fill datagaps or aid in groupings 
and read-across cases (see e.g. [9]). While predictions from the developed QSARs can be used to 
raise suspicion that a chemical may cause an AO, they are not on their own sufficient to definitively 
assess this. For this purpose, they should be used e.g. in combination with relevant AOPs, and 
together this information can feed into an IATA on chemical assessment. The QSAR models are all 
based on data from in vitro studies and it is therefore important to also include information of a 
chemical’s toxicokinetics in the assessment [10]. The guidance document for triggers of the EOGRTS 
DNT cohort inclusion under REACH is still under development [11], and, depending on its outcome, it 
is likely that the QSAR models in combination with relevant DNT AOP(s) can be included in future 
triggers for DNT testing in EOGRTS. 
4.3 Concluding Remarks  
The validation studies show that the developed global QSAR models for the selected MIEs of thyroid-
related AOPs and the ER agonism model are robust and highly predictive. The application of the 
models to predict large inventories containing 10,000s of man-made chemicals showed that these 
global models are able to generate reliable predictions for more than half of the chemicals in the 
inventories. In this way, the models were able to greatly expand the knowledge derived from 
experimental data on thousands of chemicals to provide prediction information on tens of 
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thousands of untested chemical structures for their potential interaction with MIEs in relevant AOPs. 
The QSAR models of this thesis can in this way aid in the human safety evaluation of chemicals. 
4.4 Perspectives 
All the models developed in this PhD projects will be used for screening a structure set of more than 
640,000 structures, and the predictions will be made freely available in the online Danish (Q)SAR 
Database [12]. Furthermore, the models will also been made available in a free, online QSAR model 
website (under construction), where they can be applied to predict the activity of user-submitted 
structures. If additional and adequate experimental data for the modeled MIEs become available, 
this can possibly in the future be used for further validation studies of the models and/or merged 
with the existing training sets to build larger QSARs with enhanced ADs that possibly can predict 
larger portions of the chemical universe. 
The QSAR models in this PhD project only cover a few of the mechanisms in the thyroid system and 
other mechanisms not covered in the present PhD project include inhibition of NIS or deiodinases, 
interaction with TTR, TBG, TRs or TSH receptor as well as interaction with membrane transport 
proteins [10]. For most of these mechanisms there were either not (enough) experimental data 
available during the course of the PhD, e.g. NIS inhibition, or the available datasets were assessed 
sub-optimal for global QSAR development, for example due to too few known actives, e.g. for TR 
binding [10]. Time was of course also a limiting factor for not including more mechanisms in the 
project. Efforts to develop and apply HTS assay for other relevant mechanisms in thyroid/endocrine 
disruption is ongoing [10,13,14]. Examples on thyroid-relevant HTS data underway include data for 
NIS [15] and deiodinase inhibition [16], and the data could be used for future QSAR modeling 
studies. A battery of global QSAR models for a range of relevant thyroid/endocrine mechanisms 
including those developed in this PhD and new QSARs will be of high value. In the (far) future such a 
battery of QSARs for MIEs and KEs together with relevant AOPs might replace traditional animal 
studies in regulatory toxicology.  
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QMRF: Model for mammalian Estrogen Receptor agonism in vitro (CERAPP) 
 
1. QSAR identifier  
1.1 QSAR identifier (title) 
Leadscope Enterprise model for the U.S. EPA overall conclusion regarding mammalian Estrogen 
Receptor agonism in vitro (CERAPP), model made by the Danish QSAR Group at DTU Food.  
1.2 Other related models 
No 
 
2. General information 
2.1 Date of QMRF 
June 2014. 
2.2 QMRF author(s) and contact details  
QSAR Group at DTU Food; 
Danish National Food Institute at the Technical University of Denmark;  
http://qsar.food.dtu.dk/; 
qsar@food.dtu.dk 
 
Sine Abildgaard Rosenberg; 
National Food Institute at the Technical University of Denmark; 
siro@food.dtu.dk 
 
Eva Bay Wedebye; 
National Food Institute at the Technical University of Denmark; 
ebawe@food.dtu.dk 
 
Nikolai Georgiev Nikolov; 
National Food Institute at the Technical University of Denmark; 
nign@food.dtu.dk  
 
Marianne Dybdahl; 
National Food Institute at the Technical University of Denmark; 
mdyb@food.dtu.dk 
 
2.3 Date of QMRF update(s) 
April 2017. 
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2.4 QMRF update(s) 
1 
2.5 Model developer(s) and contact details  
Sine Abildgaard Rosenberg; 
National Food Institute at the Technical University of Denmark; 
siro@food.dtu.dk 
 
Eva Bay Wedebye; 
National Food Institute at the Technical University of Denmark; 
ebawe@food.dtu.dk  
 
Nikolai Georgiev Nikolov; 
National Food Institute at the Technical University of Denmark; 
nign@food.dtu.dk 
 
Marianne Dybdahl; 
National Food Institute at the Technical University of Denmark; 
mdyb@food.dtu.dk  
 
Danish QSAR Group at DTU Food; 
National Food Institute at the Technical University of Denmark; 
http://qsar.food.dtu.dk/;  
qsar@food.dtu.dk 
 
2.6 Date of model development and/or publication 
June 2014. 
2.7 Reference(s) to main scientific papers and/or software package 
Roberts, G., Myatt, G. J., Johnson, W. P., Cross, K. P., and Blower, P. E. J. (2000) LeadScope: Software 
for Exploring Large Sets of Screening Data. Chem. Inf. Comput. Sci., 40, 1302-1314. doi: 
10.1021/ci0000631 
Cross, K.P., Myatt, G., Yang, C., Fligner, M.A., Verducci, J.S., and Blower, P.E. Jr. (2003) Finding 
Discriminating Structural Features by Reassembling Common Building Blocks. J. Med. Chem., 46, 
4770-4775. doi:10.1021/jm0302703 
Valerio, L. G., Yang, C., Arvidson, K. B., and Kruhlak, N. L. (2010) A structural feature-based 
computational approach for toxicology predictions. Expert Opin. Drug Metab. Toxicol., 6:4, 505-518. 
doi: 10.1517/17425250903499286 
2.8 Availability of information about the model 
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The training set was kindly provided by the U.S. Environmental Protection Agency (EPA) and is non-
proprietary. The model algorithm is proprietary from commercial software. This model was made for 
the U.S. EPA CERAPP project. 
 
3. Defining the endpoint  
3.1 Species 
Bovine, mouse and human cell lines (18 biochemical and cell-based in vitro assays). 
 
3.2 Endpoint 
QMRF 4. Human Health Effects 
QMRF 4.18.b. Receptor binding and gene expression (Estrogen Receptor) 
3.3 Comment on endpoint  
There is increasing evidence that a variety of environmental chemicals have the potential to disrupt 
the endocrine system by mimicking or inhibiting endogenous hormones such as estrogens and 
androgens. These endocrine disrupting chemicals (EDCs) may adversely affect development and/or 
reproductive function. 
 
Natural estrogens are involved in the development and adult function of organs of the female 
genital tract, neuroendocrine tissues and the mammary glands; their role in reproduction spans from 
maintenance of the menstrual cycle to pregnancy and lactation. These effects are primarily 
mediated through the estrogen receptors (ERs), members of the nuclear receptor superfamily. 
When estrogen binds to the ER in the cytoplasm a receptor-hormone complex dimer is formed. This 
dimer translocates to the nucleus, where it recruits co-factors to form the active transcription factor 
(TF) complex.  The active TF binds to the estrogen response element upstream to the target gene. 
This binding activates transcription of mRNA and subsequent translation to proteins that exert the 
hormone effects. Two isoforms of the ER exists in humans, alpha and beta, and both are widely 
expressed in different tissue types although there are some differences in their expression pattern.  
Exogenous compounds able to bind to and activate the ERs (i.e. ER agonists) have the ability mimic 
natural estrogens and cause adverse effects to the reproductive system. Likewise, exogenous 
compounds that bind to the ERs without subsequent activation (i.e. ER antagonists) can potentially 
disturb the effect of the natural estrogens by blocking the receptors. 
 
Results from 18 in vitro high-throughput screening assays that probe the ER signalling pathway in a 
mammalian system were integrated in a computational network model (Judson et al. 2014). The 
assays were a combination of biochemical and cell-based in vitro assays and probe perturbations of 
the ER pathway at multiple sites: receptor binding, receptor dimerization, DNA binding of the active 
transcription factor, gene transcription and changes in ER-induced cell growth kinetics. The network 
model uses activity patterns across the 18 in vitro assays to predict whether the chemical is an ER 
agonist, an ER antagonist, or instead is causing activity through narrow (technology-specific) or 
broad assay interference. For example, if a chemical is active in all of the assays in the ER agonism 
pathway of the network model a score for agonism is calculated as the AUC for the accumulated Hill 
model (based on the AC50 from the assays). If none or only parts of the assays in the ER agonist 
pathway are active, the chemical is a clear negative or is causing some form of assay interference 
(narrow or broad depending on which assays in the pathway that are active), respectively. These 
chemicals have an ER agonist score of 0 and are all assumed to be negative (Judson et al. 2014). 
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In order to make a classification model, compounds with an ER agonist score of 0 were defined as 
inactives and compounds with an AUC score of 0.1 or above were defined as an ER agonist. 
  
3.4 Endpoint units 
No units, 1 for positives and 0 for negatives. 
3.5 Dependent variable 
Mammalian Estrogen Receptor agonist: positive or negative.  
 
3.6 Experimental protocol 
See S1, Appendix 1 in Judson et al. 2015. 
3.7 Endpoint data quality and variability 
The data is expected to be of high quality because of the integration of several assays to exclude 
false positives caused by narrow (technology-specific) or broad assay interference. Also, the 
variability in the data is expected to be low as for each assay all chemicals have been tested in the 
same laboratory and the process of assigning an ER agonist score using the network model (see 3.2) 
has been equal for all chemicals. 
 
4. Defining the algorithm  
4.1 Type of model 
A categorical QSAR model based on structural features and numeric molecular descriptors. 
4.2 Explicit algorithm 
This is a categorical QSAR model made by use of partial logistic regression (PLR). Because of the 
imbalanced training set the “mother model” is a composite model consisting of ten submodels, using 
all the positives (80 chemicals) in each of these and different sub-sets of the negatives (see 4.5). The 
specific implementation is proprietary within the Leadscope software. 
4.3 Descriptors in the model 
structural features, 
aLogP, 
polar surface area, 
number of hydrogen bond donors, 
Lipinski score, 
number of rotational bonds, 
parent atom count, 
parent molecular weight, 
number of hydrogen bond acceptors 
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4.4 Descriptor selection  
Leadscope Predictive Data Miner (LPDM) is a commercial software program for systematic sub-
structural analysis of a compound using predefined structural features stored in a template library. 
The feature library contains approximately 27,000 structural features and the structural features 
chosen for the library are motivated by those typically found in small molecules: aromatics, 
heterocycles, spacer groups, simple substituents. Additionally, LPDM also calculates eight molecular 
descriptors for each structure: the octanol/water partition coefficient (alogP), hydrogen bond 
acceptors, hydrogen bond donors, Lipinski score, atom count, parent compound molecular weight, 
polar surface area and rotatable bonds. It is further possible to generate training set-dependent 
structural features (scaffold generation) and use these features in the model building process. 
Redundant features are removed and the remaining features are used in the model building. The 
default automatic feature selection process in LPDM selects the top 30% of the features according to 
X2-test for a binary variable, or the top and bottom 15% according to t-test for a continuous variable. 
LPDM treats numeric property data as ordinal categorical data. If the input data is continuous such 
as IC50 or cLogP data, the user can determine how values are assigned to categories: the number of 
categories and the cutoff values between categories. (Roberts et al. 2000). 
4.5 Algorithm and descriptor generation 
For descriptor generation see 4.4. 
After selection of features the LPDM program performs partial least squares (PLS) regression for a 
continuous response variable, or partial logistic regression (PLR) for a binary response variable, to 
build a predictive model. By default LPDM performs leave-one-out or leave-groups-out (in the latter 
case, the user can specify any number of repetitions and percentage of structures left out) cross 
validation on the training set depending on the size of the training set.  
In this model because of the categorical outcome in the response variable PLR was used to build the 
predictive model. Because of the unbalanced training set (i.e. 80 positives vs. 1342 negatives) ten 
submodels for smaller individual training sets consisting of the 80 positives and an equal number of 
negatives selected by random among the 1342 negatives were made. The descriptors for each of the 
ten submodels were automatically selected from the LPDM feature library based solely on the 
training set compounds used to build the individual submodel and was not affected by the training 
set chemicals in the composite “mother model”. Therefore, a different number of descriptors 
(structural features and molecular descriptors) were selected and distributed on varying number of 
PLS factors for each submodel. 
4.6 Software name and version for descriptor generation 
Leadscope Predictive Data Miner, a component of Leadscope Enterprise version 3.1.1-10. 
4.7 Descriptors/chemicals ratio 
The model system uses molecular descriptors and structural features specific to a group of 
structurally related chemicals from the global training set. Therefore estimations of the number of 
used descriptors may be difficult. In general, we estimate that the models effectively use an order of 
magnitude less descriptors than numbers of chemicals in the training set when we set our domain 
definition where we weed out low probability active and inactive predictions (see 5.1).  
 
5. Defining Applicability Domain  
5.1 Description of the applicability domain of the model 
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For assessing if a test compound is within the applicability domain of a given model LPDM examines 
whether the test compound bears enough resemblance to the training set compounds used for 
building the model (i.e. structural domain analysis). This is done by calculating the distance between 
the test compound and all compounds in the training set (distance equals 1 - similarity). The 
similarity score is based on the Tanimoto method. The numbers of neighbors is defined as the 
numbers of compounds in the training set that have a distance ≤ 0.7 with respect to the test 
compound. The higher the number of neighbors the more reliable the prediction for the test 
compound. Statistics of the distances are also calculated. Effectively no predictions are made for test 
compounds which are not within the structural domain of the model or for which the molecular 
descriptors could not be generated. 
In addition to the general LPDM structural domain definition the Danish QSAR group has applied a 
further requirement to the applicability domain of the model. Only predictions with probability (p) 
equal to or greater than 0.7 were accepted for actives. Predictions with p equal to or less than 0.3 
were accepted for inactives. Predictions within the structural domain but with p = [0.5;0.7[ and p = 
]0.3;0.5[ where defined as positives out of applicability domain and negatives out of applicability 
domain, respectively. When these predictions were wed out the performance increased at the 
expense of a reduced coverage. 
5.2 Method used to assess the applicability domain 
The system does not generate predictions for test compounds which are not in the structural 
domain or for which the molecular descriptors could not be generated.  
Only predictions with probability equal to or greater than 0.7 were accepted for actives and 
predictions with probability equal to or less than 0.3 were accepted for inactives. 
5.3 Software name and version for applicability domain assessment 
Leadscope Predictive Data Miner (LPDM), a component of Leadscope Enterprise version 3.1.1-10. 
5.4 Limits of applicability 
The Danish QSAR group applies an overall definition of structures acceptable for QSAR processing 
which is applicable for all the in-house QSAR software, i.e. not only LPDM. According to this 
definition accepted structures are organic substances with an unambiguous structure, i.e. so-called 
discrete organics defined as: organic compounds with a defined two dimensional (2D) structure 
containing at least two carbon atoms, only certain atoms (H, Li, B, C, N, O, F, Na, Mg, Si, P, S, Cl, K, 
Ca, Br, and I), and not mixtures with two or more ‘big components’ when analyzed for ionic bonds 
(for a number of small known organic ions assumed not to affect toxicity the ‘parent molecule’ is 
accepted). Calculation 2D structures (SMILES and/or SDF) are generated by stripping off ions (of the 
accepted list given above). Thus, all the training set chemicals are used in their non-ionized form. See 
5.1 for further applicability domain definition.  
 
6. Internal validation 
6.1 Availability of the training set 
Yes 
6.2 Available information for the training set 
SMILES 
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6.3 Data for each descriptor variable for the training set 
No 
6.4 Data for the dependent variable for the training set 
All 
6.5 Other information about the training set 
1422 compounds are in the training set: 80 positives and 1342 negatives.  
 
6.6 Pre-processing of data before modeling 
The results from the 18 ER in vitro assays were integrated using a network model and scores for ER 
agonism and ER antagonism were assigned to each chemical by US EPA (Judson et al. 2014). The ER 
agonist scores were categorized in order to make a categorical QSAR model. A cut off of 0.1 and 
above were set and chemicals in this category were defined as being ER agonists (80 chemicals). 
Chemicals with an ER agonist score of 0 were defined as not being ER agonists (1342 chemicals). The 
chemicals with an ER agonist score between 0 and 0.1 were excluded from the training set.  
6.7 Statistics for goodness-of-fit 
Not performed. 
6.8 Robustness – Statistics obtained by leave-one-out cross-validation  
Not performed. (It is not a preferred measurement for evaluating large models).  
6.9 Robustness – Statistics obtained by leave-many-out cross-validation 
A five times two-fold cross-validation was performed. This was done by randomly removing 50% of 
the full training set used to make the “mother model”, where the 50% contains the same ratio of 
positive and negatives as the full training set. A new model (validation submodel) was created on the 
remaining 50% using the same settings in LPDM but with no information from the “mother model” 
regarding descriptor selection etc. The validation submodel was applied to predict the removed 50% 
(within the defined applicability domain). Likewise, a validation submodel was made on the removed 
50% of the training set and this model was used to predict the other 50% (within the defined 
applicability domain). This was repeated five times.  
Predictions from the ten submodels were pooled and Coopers statistics for the composite “mother 
model” were calculated. This gave the following results for the 74,0% (5263*100%/(5*1422) of the  
predictions which were within the applicability domains of the respective sub-models:  
− Sensitivity (true positives / (true positives + false negatives)): 270/(270+65) = 80.60% 
− Specificity (true negatives / (true negatives + false positives)): 4650/(4650+278) = 94.36% 
− Concordance ((true positives + true negatives) / (true positives + true negatives + false 
positives + false negatives)): 4920/5263 = 93.48% 
− Balanced accuracy ((Sensitivity + specificity)/2): (80.6% + 94.36%)/2 = 87.5% 
6.10 Robustness - Statistics obtained by Y-scrambling 
Not performed. 
6.11 Robustness - Statistics obtained by bootstrap 
Not performed. 
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6.12 Robustness - Statistics obtained by other methods 
Not performed. 
 
7. External validation  
7.1 Availability of the external training set 
7.2 Available information for the external training set 
7.3 Data for each descriptor variable for the external training set 
7.4 Data for the dependent variable for the external training set 
7.5 Other information about the training set  
7.6 Experimental design of test set 
7.7 Predictivity – Statistics obtained by external validation 
7.8 Predictivity – Assessment of the external validation set 
7.9 Comments on the external validation of the model  
External validation was not performed.  
 
8. Mechanistic interpretation  
8.1 Mechanistic basis of the model 
The global model identifies structural features and molecular descriptors which in the model 
development was found to be statistically significant associated with effect. Many predictions may 
indicate modes of action that are obvious for persons with expert knowledge for the endpoint.  
8.2 A priori or posteriori mechanistic interpretation 
The identified structural features and molecular descriptors may provide basis for mechanistic 
interpretation.  
8.3 Other information about the mechanistic interpretation 
 
9. Miscellaneous information 
9.1 Comments 
The model can be used to predict if a chemical is an ER agonist (i.e. has an ER agonist score equal to 
or above 0.1) according to the network model based on the 18 ER pathway in vitro assays. 
9.2 Bibliography 
Judson, R.S., Magpantay, F.M., Chickarmane, V., Haskell, C., Tania, N., Taylor, J., Xia, M., Huang, R., 
Rotroff, D.M., Filer, D.L., Houck, K.A., Martin, M.T., Sipes, N., Richard, A.M., Mansouri, K., Setzer, 
R.W., Knudsen, T.B., Crofton, K.M., and Thomas, R.S. (2015) Integrated Model of Chemical 
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Perturbations of a Biological Pathway Using 18 In Vitro Thigh-Throughput Screening Assays for the 
Estrogen Receptor. Toxicol.Sci., 148, 137-154. doi:10.1093/toxsci/kfv168 
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